⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL136994 | 1.00 | — | — | |
| SCHEMBL88559 | 1.00 | — | — | |
| SCHEMBL22069894 | 0.98 | PIK3CD (0.32) | — | |
| Lithium SCHEMBL38658000 | 0.98 | PIK3CD (0.32) | — | |
| SCHEMBL9374856 | 0.98 | PIK3CD (0.32) | — | |
| SCHEMBL16045961 | 0.83 | — | — | |
| SCHEMBL21378367 | 0.83 | — | — | |
| SCHEMBL22158785 | 0.83 | — | — | |
| SCHEMBL22201554 | 0.83 | — | — | |
| SCHEMBL16055022 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 917 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120192264-A | Preparation method of itramod | 深圳市华先医药科技有限公司 | 2025-06-24 | — | — | CN | claimed |
| US-20240154124-A1 | NEGATIVE ELECTRODE PLATE AND LITHIUM-ION BATTERY COMPRISING SAME | ZHUHAI COSMX BATTERY CO., LTD. (CN) | 2024-05-09 | — | — | US | claimed |
| WO-2024040267-A2 | DIRECT SYNTHESIS OF N-(3-SUBSTITUTED-CHROMAN-4-YL)-7H- PYRROLO[2,3-D]PYRIMIDIN-4-AMINES AND DERIVATIVES THEREOF | MITOKININ, INC. (US) | 2024-02-22 | — | — | WO | claimed |
| CN-117186150-A | Preparation method of LFA-1 inhibitor | 维眸生物科技（上海）有限公司 | 2023-12-08 | — | — | CN | claimed |
| CN-105638692-A | Pesticide for liriomyza huidobrensis | 烟台顺隆化工科技有限公司 | 2016-06-08 | — | — | CN | claimed |
| US-RE38947-E1 | Method of enantioselectively catalyzing a reaction | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2006-01-24 | — | — | US | claimed |
| US-20050272667-A1 | Analogs and derivatives of (S,S,R)-(-)-actinonin and uses therefor | SCHEINBERG DAVID | 2005-12-08 | — | — | US | claimed |
| EP-1372692-A4 | ASYMMETRIC SYNTHESIS OF (S, S, R)-(-)-ACTINONIN AND ITS ANALOGS AND USES THEREFOR | SLOAN KETTERING INST CANCER (US) | 2005-10-26 | — | — | EP | claimed |
| US-6887887-B2 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2005-05-03 | — | — | US | claimed |
| US-20040019083-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-01-29 | — | — | US | claimed |
| EP-1372692-A2 | ASYMMETRIC SYNTHESIS OF (S, S, R)-(-)-ACTINONIN AND ITS ANALOGS AND USES THEREFOR | Sloan Kettering Institute For Cancer Research (US) | 2004-01-02 | — | — | EP | claimed |
| US-6660741-B2 | Coupling an O-protected methoxypyrrolidine or derivatives with N-protected amino acid 2,5-dioxo-pyrrolidinyl ester to form intermediate, deportecting with trifluoroacetic acid to form pyrrolidine-1-carbonyl-2-methylamine or derivatives | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-12-09 | — | — | US | claimed |
| US-20020198156-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2002-12-26 | — | — | US | claimed |
| WO-2002074050-A2 | ASYMMETRIC SYNTHESIS OF (S, S, R)-(-)-ACTINONIN AND ITS ANALOGS AND USES THEREFOR | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2002-09-26 | — | — | WO | claimed |
| EP-0594608-B1 | CHIRAL CATALYSTS FOR ENANTIOSELECTIVE SYNTHESIS | RES CORP TECHNOLOGIES INC (US) | 1997-10-15 | — | — | EP | claimed |
| EP-0594608-A1 | CHIRAL CATALYSTS FOR ENANTIOSELECTIVE SYNTHESIS. | RES CORP TECHNOLOGIES INC (US) | 1994-05-04 | — | — | EP | claimed |
| EP-0594608-A4 | CHIRAL CATALYSTS FOR ENANTIOSELECTIVE SYNTHESIS. | RES CORP TECHNOLOGIES INC (US) | 1993-03-15 | — | — | EP | claimed |
| WO-1991014672-A1 | CHIRAL CATALYSTS FOR ENANTIOSELECTIVE SYNTHESIS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1991-10-03 | — | — | WO | claimed |
| EP-0197432-A2 | Enantioselective process for producing 1-beta-methylcarbapenem antibiotic intermediates | MERCK & CO. INC. (US) | 1986-10-15 | — | — | EP | claimed |
| CN-122036599-A | Dibenzylbutane lignan LCA analogue, and preparation method and application thereof | 浙江中医药大学 | 2026-05-15 | — | — | CN | disclosed |
| US-20260091081-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-04-02 | — | — | US | disclosed |
| EP-4714446-A2 | PHARMACEUTICAL COMPOUNDS | Nxera Pharma UK Limited (GB) | 2026-03-25 | — | — | EP | disclosed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | disclosed |
| US-12570648-B2 | 6,7-dihydro-5H-pyrido[2,3-c]pyridazine derivatives and related compounds as Bcl-xL protein inhibitors and pro-apoptotic agents for treating cancer | LES LABORATOIRES SERVIER (FR) | 2026-03-10 | — | — | US | disclosed |
| EP-4696692-A1 | CRYSTAL OF NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-02-18 | — | — | EP | disclosed |
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| US-12441735-B2 | Nitrogen-containing heterocyclic compound having NRF2 activation effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-10-14 | — | — | US | disclosed |
| US-20250313539-A1 | Alpha, Beta-UNSATURATED AMIDE COMPOUND, AND PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | KUNMING INSTITUTE OF ZOOLOGY, CHINESE ACADEMY OF SCIENCES (CN) | 2025-10-09 | — | — | US | disclosed |
| US-12414954-B2 | POLQ inhibitors | ASTRAZENECA AB (SE) | 2025-09-16 | — | — | US | disclosed |
| EP-4612149-A1 | PYRIDO[2,3-D]PYRIMIDIN-2-AMINE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Cancer Research Technology Limited (GB) | 2025-09-10 | — | — | EP | disclosed |
| CN-120192264-A | Preparation method of itramod | 深圳市华先医药科技有限公司 | 2025-06-24 | — | — | CN | disclosed |
| US-20250195530-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2025-06-19 | — | — | US | disclosed |
| US-20250171457-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-05-29 | — | — | US | disclosed |
| WO-2025098432-A1 | mIDH1/NAMPT DUAL-TARGET INHIBITOR AND USE THEREOF | 中国药科大学 | 2025-05-15 | — | — | WO | disclosed |
| EP-4553069-A1 | ALPHA,ß-UNSATURATED AMIDE COMPOUND, AND PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2025-05-14 | — | — | EP | disclosed |
| CN-119798181-A | (R) -4-isopropyl-3- ((R) -2-methyl-5-hexenoyl) oxazolidin-2-one and application thereof in synthesis of inchworm sex pheromone component of Western iron yew | 山东省农业科学院 | 2025-04-11 | — | — | CN | disclosed |
| CN-119790041-A | Alpha, beta-unsaturated amide compounds, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2025-04-08 | — | — | CN | disclosed |
| US-20250084093-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-03-13 | — | — | US | disclosed |
| CN-117510484-B | MIDH1/NAMPT double-target inhibitor and application thereof | 中国药科大学 | 2024-11-22 | — | — | CN | disclosed |
| EP-3601229-B1 | TETRAHYDRO-BENZO[D]AZEPINE DERIVATIVES AS GPR120 MODULATORS | CALDAN THERAPEUTICS LTD (GB) | 2024-11-06 | — | — | EP | disclosed |
| EP-4446312-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-10-16 | — | — | EP | disclosed |
| US-20240294482-A1 | METHOD FOR CATALYTICALLY ACTIVATING CARBON DIOXIDE AS CARBONYLATION REAGENT WITH INORGANIC SULFUR | INNER MONGOLIA UNIVERSITY OF TECHNOLOGY (CN) | 2024-09-05 | — | — | US | disclosed |
| EP-4413985-A2 | PHARMACEUTICAL COMPOUNDS | Nxera Pharma UK Limited (GB) | 2024-08-14 | — | — | EP | disclosed |
| CN-118488944-A | Nitrogen-containing heterocyclic compound having Nrf2 activation | 中外制药株式会社 | 2024-08-13 | — | — | CN | disclosed |
| CN-118475581-A | CCR4 small molecule antagonist and application thereof | 瑞石生物医药有限公司 | 2024-08-09 | — | — | CN | disclosed |
| US-20240254163-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. | 2024-08-01 | — | — | US | disclosed |
| US-20240246943-A1 | MULTIFACETED APPROACH TO NOVEL INTERLEUKIN-6 INHIBITORS | University of Florida Research Fooundation, Incorporated (US) | 2024-07-25 | — | — | US | disclosed |
| US-20240217930-A1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-07-04 | — | — | US | disclosed |
| US-20240217930-A1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-07-04 | — | — | US | disclosed |
| US-20240217930-A1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-07-04 | — | — | US | disclosed |
| WO-2024121753-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-13 | — | — | WO | disclosed |
| US-11998584-B2 | Conjugate of a tubulysin analog with branched linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2024-06-04 | — | — | US | disclosed |
| WO-2024094962-A1 | PYRIDO[2,3-D]PYRIMIDIN-2-AMINE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-05-10 | — | — | WO | disclosed |
| US-20240154124-A1 | NEGATIVE ELECTRODE PLATE AND LITHIUM-ION BATTERY COMPRISING SAME | ZHUHAI COSMX BATTERY CO., LTD. (CN) | 2024-05-09 | — | — | US | disclosed |
| CN-114450284-B | 6, 7-Dihydro-5H-pyrido [2,3-C ] pyridazine derivatives as BCL-XL protein inhibitors | 法国施维雅药厂 | 2024-05-07 | — | — | CN | disclosed |
| US-11964956-B2 | Cannabinergic compounds and uses thereof | NORTHEASTERN UNIVERSITY (US) | 2024-04-23 | — | — | US | disclosed |
| CN-117858867-A | SARS-COV-2 MPRO inhibitor compounds | 赫普泰雅治疗有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-111825666-B | Dimeric or multimeric forms of mutant IDH inhibitors | 上海仕谱生物科技有限公司 | 2024-03-08 | — | — | CN | disclosed |
| WO-2024040267-A2 | DIRECT SYNTHESIS OF N-(3-SUBSTITUTED-CHROMAN-4-YL)-7H- PYRROLO[2,3-D]PYRIMIDIN-4-AMINES AND DERIVATIVES THEREOF | MITOKININ, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| EP-4313305-A1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | Heptares Therapeutics Limited (GB) | 2024-02-07 | — | — | EP | disclosed |
| CN-117510484-A | mIDH1/NAMPT double-target inhibitor and application thereof | 中国药科大学 | 2024-02-06 | — | — | CN | disclosed |
| US-11873281-B2 | Conjugates of cell binding molecules with cytotoxic agents | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2024-01-16 | — | — | US | disclosed |
| CN-117402123-A | Alpha, beta-unsaturated amide compounds, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2024-01-16 | — | — | CN | disclosed |
| WO-2024008166-A1 | α,β-UNSATURATED AMIDE COMPOUND, AND PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 中国科学院上海药物研究所 | 2024-01-11 | — | — | WO | disclosed |
| US-11866515-B2 | Hemiasterlin derivatives for conjugation and therapy | SUTRO BIOPHARMA, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| EP-4003989-B1 | 6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER | SERVIER LAB (FR) | 2023-12-27 | — | — | EP | disclosed |
| CN-117186150-A | Preparation method of LFA-1 inhibitor | 维眸生物科技（上海）有限公司 | 2023-12-08 | — | — | CN | disclosed |
| EP-3953334-B1 | NOVEL SYNTHETIC OPTIONS TOWARDS THE MANUFACTURE OF (6R,10S)-10- {4-[5-CHLORO-2-(4-CHLORO-1H-1,2,3-TRIAZOL-1-YL)PHENYL]-6-OXO-1(6H)- PYRIMIDINYL}- 1-(DIFLUOROMETHYL)-6-METHYL-1,4,7,8,9,10-HEXAHYDRO-11,15 -(METHENO)PYRAZOLO [4,3-B] [1,7] DIAZACYCLOTETRADECIN-5(6H)-ONE | BRISTOL MYERS SQUIBB CO (US) | 2023-11-22 | — | — | EP | disclosed |
| CN-116536375-B | Chemo-enzymatic synthesis method of merocyclophanes compound and application thereof | 北京大学深圳研究生院 | 2023-11-10 | — | — | CN | disclosed |
| CN-110891938-B | Tetrahydro-benzo [ D ] azepine derivatives as GPR120 modulators | 卡尔丹治疗有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116745273-A | Method for catalyzing and activating carbon dioxide by using inorganic sulfur as carbonylation reagent | 内蒙古工业大学 | 2023-09-12 | — | — | CN | disclosed |
| CN-116536375-A | Chemo-enzymatic synthesis method of merocyclophanes compound and application thereof | 北京大学深圳研究生院 | 2023-08-04 | — | — | CN | disclosed |
| WO-2023146785-A1 | PYRROLIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023143194-A1 | CCR4 SMALL MOLECULE ANTAGONIST AND USE THEREOF | 瑞石生物医药有限公司 | 2023-08-03 | — | — | WO | disclosed |
| CN-107216312-B | Compound with mutant IDH inhibitory activity, preparation method and application thereof | 上海海和药物研究开发股份有限公司 | 2023-08-01 | — | — | CN | disclosed |
| WO-2023132369-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | 中外製薬株式会社 | 2023-07-13 | — | — | WO | disclosed |
| CN-116410182-A | CCR4 small molecule antagonist and application thereof | 瑞石生物医药有限公司 | 2023-07-11 | — | — | CN | disclosed |
| CN-114127060-B | Dimeric or multimeric forms of mutant IDH inhibitors | 上海仕谱生物科技有限公司 | 2023-06-13 | — | — | CN | disclosed |
| US-20230165931-A1 | A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230165930-A1 | CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230149502-A1 | CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-05-18 | — | — | US | disclosed |
| WO-2023070618-A1 | LIGHT-EMITTING ELEMENT INK AND APPLICATION OF POLYMER IN SAME, AND DISPLAY APPARATUS AND MANUFACTURING METHOD THEREFOR | 华为技术有限公司 | 2023-05-04 | — | — | WO | disclosed |
| WO-2023046089-A1 | NEGATIVE ELECTRODE PLATE AND LITHIUM-ION BATTERY COMPRISING NEGATIVE ELECTRODE PLATE | 珠海冠宇电池股份有限公司 | 2023-03-30 | — | — | WO | disclosed |
| WO-2023046091-A1 | SOLID ELECTROLYTE AND USE THEREOF | 珠海冠宇电池股份有限公司 | 2023-03-30 | — | — | WO | disclosed |
| WO-2023046181-A1 | SOLID ELECTROLYTE AND LITHIUM ION BATTERY COMPRISING SAME | 珠海冠宇电池股份有限公司 | 2023-03-30 | — | — | WO | disclosed |
| CN-113813934-B | Preparation and application of hydrophilic/hydrophobic @ acid/base equilibrium chromatographic stationary phase | 中国科学院兰州化学物理研究所 | 2023-03-03 | — | — | CN | disclosed |
| US-11584765-B2 | Polycyclic amines as sigma receptor modulators | Ecstasy LLC (US) | 2023-02-21 | — | — | US | disclosed |
| CN-110662541-B | Polycyclic amines as opioid receptor modulators | 王晓冬 | 2023-02-10 | — | — | CN | disclosed |
| US-20230025327-A1 | CONJUGATES OF TUBULYSIN DERIVATIVES AND CELL BINDING MOLECULES AND METHODS OF MAKING | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| US-20230025327-A1 | CONJUGATES OF TUBULYSIN DERIVATIVES AND CELL BINDING MOLECULES AND METHODS OF MAKING | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| CN-110291085-B | Mutant isocitrate dehydrogenase inhibitors, compositions and methods thereof | 艾科生物科技有限公司 | 2023-01-24 | — | — | CN | disclosed |
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-12 | — | — | US | disclosed |
| CN-109912683-B | Cytotoxin molecule, conjugate, preparation method and application thereof | 杭州多禧生物科技有限公司 | 2023-01-06 | — | — | CN | disclosed |
| US-20220411442-A1 | POLYCYCLIC AMINES AS OPIOID RECEPTOR MODULATORS | Ecstasy LLC | 2022-12-29 | — | — | US | disclosed |
| CN-115505029-A | Cytotoxin molecule, conjugate, preparation method and application thereof | 杭州多禧生物科技有限公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-107428801-B | Hemiasterlin derivatives for coupling and therapy | 苏特罗生物制药公司 | 2022-12-20 | — | — | CN | disclosed |
| US-20220363677-A1 | 6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER | VERNALIS (R&D) LTD (GB) | 2022-11-17 | — | — | US | disclosed |
| WO-2022226133-A1 | MULTIFACETED APPROACH TO NOVEL INTERLEUKIN-6 INHIBITORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022208113-A1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-10-06 | — | — | WO | disclosed |
| US-11447503-B2 | Pyridine carbamates and their use as GLUN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-09-20 | — | — | US | disclosed |
| US-20220267309-A1 | DIMERIC OR POLYMERIC FORM OF MUTANT IDH INHIBITOR | Epitas Biosciences (shanghai) Co., Ltd. (CN) | 2022-08-25 | — | — | US | disclosed |
| US-20220249594-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2022-08-11 | — | — | US | disclosed |
| US-11396505-B2 | Inhibitors of CaMKK2 and uses of same | NEW YORK UNIVERSITY (US) | 2022-07-26 | — | — | US | disclosed |
| CN-114716506-A | Hemiasterlin derivatives for conjugation and therapy | 苏特罗生物制药公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2022135355-A1 | METHOD FOR CATALYTICALLY ACTIVATING CARBON DIOXIDE AS CARBONYLATION REAGENT WITH INORGANIC SULFUR | 内蒙古工业大学 | 2022-06-30 | — | — | WO | disclosed |
| WO-2022135355-A1 | METHOD FOR CATALYTICALLY ACTIVATING CARBON DIOXIDE AS CARBONYLATION REAGENT WITH INORGANIC SULFUR | 内蒙古工业大学 | 2022-06-30 | — | — | WO | disclosed |
| EP-4003989-A1 | 6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER | Les Laboratoires Servier (FR) | 2022-06-01 | — | — | EP | disclosed |
| CN-114450284-A | 6, 7-dihydro-5H-pyrido [2,3-C ] pyridazine derivatives and related compounds as BCL-XL protein inhibitors and pro-apoptotic agents for the treatment of cancer | 法国施维雅药厂 | 2022-05-06 | — | — | CN | disclosed |
| EP-3991752-A1 | CELL-BINDING MOLECULE-TUBULYSIN DERIVATIVE CONJUGATE AND PREPARATION METHOD THEREFOR | Hangzhou Dac Biotech Co., Ltd (CN) | 2022-05-04 | — | — | EP | disclosed |
| EP-3986476-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | Hangzhou Dac Biotech Co., Ltd. (CN) | 2022-04-27 | — | — | EP | disclosed |
| EP-3983074-A1 | PYRIDINE CARBAMATES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2022-04-20 | — | — | EP | disclosed |
| EP-3964508-A1 | DIMERIC OR POLYMERIC FORM OF MUTANT IDH INHIBITOR | Epitas Biosciences (Shanghai) Co., Ltd. (CN) | 2022-03-09 | — | — | EP | disclosed |
| EP-3964508-A1 | DIMERIC OR POLYMERIC FORM OF MUTANT IDH INHIBITOR | Epitas Biosciences (Shanghai) Co., Ltd. (CN) | 2022-03-09 | — | — | EP | disclosed |
| CN-114127060-A | Dimeric or multimeric forms of mutant IDH inhibitors | 上海仕谱生物科技有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-114040778-A | Cell binding molecule-Tubulysin derivative conjugate and preparation method thereof | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | disclosed |
| CN-114040781-A | Formulation of conjugate of TUBULYSIN derivative and cell binding molecule | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | disclosed |
| CN-114007691-A | Pyridine carbamates and their use as GluN2B receptor modulators | 詹森药业有限公司 | 2022-02-01 | — | — | CN | disclosed |
| US-11220483-B2 | Tetrahydro-benzo[d]azepine derivatives as GPR120 modulators | CALDAN THERAPEUTICS LTD (GB) | 2022-01-11 | — | — | US | disclosed |
| CN-113871711-A | Negative pole piece and lithium ion battery comprising same | 珠海冠宇电池股份有限公司 | 2021-12-31 | — | — | CN | disclosed |
| CN-113871619-A | Positive plate and application thereof | 珠海冠宇电池股份有限公司 | 2021-12-31 | — | — | CN | disclosed |
| CN-113871699-A | Solid electrolyte and lithium ion battery comprising same | 珠海冠宇电池股份有限公司 | 2021-12-31 | — | — | CN | disclosed |
| CN-113871708-A | Solid electrolyte and application thereof | 珠海冠宇电池股份有限公司 | 2021-12-31 | — | — | CN | disclosed |
| CN-113871709-A | Positive pole piece and solid-state battery comprising same | 珠海冠宇电池股份有限公司 | 2021-12-31 | — | — | CN | disclosed |
| US-20210403460-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | ISOCURE BIOSCIENCES INC (US) | 2021-12-30 | — | — | US | disclosed |
| US-20210403460-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | ISOCURE BIOSCIENCES INC (US) | 2021-12-30 | — | — | US | disclosed |
| CN-113851656-A | Negative pole piece and lithium ion battery comprising same | 珠海冠宇电池股份有限公司 | 2021-12-28 | — | — | CN | disclosed |
| CN-113851655-A | Negative pole piece and lithium ion battery comprising same | 珠海冠宇电池股份有限公司 | 2021-12-28 | — | — | CN | disclosed |
| CN-113813934-A | Preparation and application of hydrophilic/hydrophobic @ acid/base equilibrium chromatographic stationary phase | 中国科学院兰州化学物理研究所 | 2021-12-21 | — | — | CN | disclosed |
| CN-109311863-B | Mutant IDH1 inhibitors | 伊莱利利公司 | 2021-10-29 | — | — | CN | disclosed |
| US-11149032-B2 | Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof | ISOCURE BIOSCIENCES INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-11149032-B2 | Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof | ISOCURE BIOSCIENCES INC. (US) | 2021-10-19 | — | — | US | disclosed |
| EP-3892305-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | Sutro Biopharma, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3862023-A1 | CONJUGATES OF CELL-BINDING MOLECULES WITH CYTOTOXIC AGENTS | Hangzhou DAC Biotech Co, Ltd (CN) | 2021-08-11 | — | — | EP | disclosed |
| CN-113195487-A | 2, 3-diaminosuccinyl conjugate linkers | 杭州多禧生物科技有限公司 | 2021-07-30 | — | — | CN | disclosed |
| US-20210198314-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. | 2021-07-01 | — | — | US | disclosed |
| US-20210198314-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. | 2021-07-01 | — | — | US | disclosed |
| EP-3250237-B1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA INC (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3543229-B1 | METHOD FOR PREPARING OPTICALLY PURE (R)-4-N-PROPYL-DIHYDROFURAN-2(3H)-ONE | BEIJING ABLEPHARMTECH CO LTD (CN) | 2021-04-14 | — | — | EP | disclosed |
| US-10975050-B2 | Process for preparing optically pure (R)-4-n-propyl-dihydrofuran-2(3H)-one | BEIJING ABLEPHARMTECH CO., LTD. (CN) | 2021-04-13 | — | — | US | disclosed |
| US-20210101878-A1 | Cannabinergic Compounds And Uses Thereof | NORTHEASTERN UNIVERSITY | 2021-04-08 | — | — | US | disclosed |
| CN-108137561-B | Indolin-2-one derivatives | 豪夫迈·罗氏有限公司 | 2021-03-26 | — | — | CN | disclosed |
| EP-3371174-B1 | INDOLIN-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2021-03-17 | — | — | EP | disclosed |
| EP-3438113-B1 | TETRADENTATE LIGAND, AND PRODUCTION METHOD THEREFOR, SYNTHETIC INTERMEDIATE THEREOF, AND TRANSITION METAL COMPLEX THEREOF | TAKASAGO PERFUMERY CO LTD (JP) | 2021-02-17 | — | — | EP | disclosed |
| WO-2021018858-A1 | 6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER | LES LABORATOIRES SERVIER (FR) | 2021-02-04 | — | — | WO | disclosed |
| WO-2021000067-A1 | CELL-BINDING MOLECULE-TUBULYSIN DERIVATIVE CONJUGATE AND PREPARATION METHOD THEREFOR | 杭州多禧生物科技有限公司 | 2021-01-07 | — | — | WO | disclosed |
| US-10882838-B2 | Cannabinergic compounds and uses thereof | NORTHEASTERN UNIVERSITY (US) | 2021-01-05 | — | — | US | disclosed |
| US-10882838-B2 | Cannabinergic compounds and uses thereof | NORTHEASTERN UNIVERSITY (US) | 2021-01-05 | — | — | US | disclosed |
| WO-2020258893-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2020-12-30 | — | — | WO | disclosed |
| US-20200392154-A1 | PYRIDINE CARBAMATES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | US | disclosed |
| WO-2020249799-A1 | PYRIDINE CARBAMATES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | WO | disclosed |
| CN-112004790-A | Novel indoleamine 2, 3-dioxygenase inhibitor and preparation method and application thereof | 信达生物制药(苏州)有限公司 | 2020-11-27 | — | — | CN | disclosed |
| US-20200369656-A1 | INHIBITORS OF CAMKK2 AND USES OF SAME | NEW YORK UNIVERSITY | 2020-11-26 | — | — | US | disclosed |
| US-10844090-B2 | Hemiasterlin derivatives for conjugation and therapy | SUTRO BIOPHARMA, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-10844090-B2 | Hemiasterlin derivatives for conjugation and therapy | SUTRO BIOPHARMA, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| WO-2020216071-A1 | DIMERIC OR POLYMERIC FORM OF MUTANT IDH INHIBITOR | 上海仕谱生物科技有限公司 | 2020-10-29 | — | — | WO | disclosed |
| WO-2020216071-A1 | DIMERIC OR POLYMERIC FORM OF MUTANT IDH INHIBITOR | 上海仕谱生物科技有限公司 | 2020-10-29 | — | — | WO | disclosed |
| CN-111825666-A | Dimeric or multimeric forms of mutant IDH inhibitors | 上海仕谱生物科技有限公司 | 2020-10-27 | — | — | CN | disclosed |
| US-10807976-B2 | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200317619-A1 | TETRAHYDRO-BENZO[D]AZEPINE DERIVATIVES AS GPR120 MODULATORS | CALDAN THERAPEUTICS LTD. (GB) | 2020-10-08 | — | — | US | disclosed |
| CN-107311911-B | Preparation method of chiral intermediate of nilapanib | 钟桂发 | 2020-09-08 | — | — | CN | disclosed |
| US-20200276261-A1 | A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2020-09-03 | — | — | US | disclosed |
| WO-2020141439-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2020-07-09 | — | — | WO | disclosed |
| EP-3464281-B1 | MUTANT IDH1 INHIBITORS | LILLY CO ELI (US) | 2020-07-08 | — | — | EP | disclosed |
| US-20200206233-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2020-07-02 | — | — | US | disclosed |
| US-10696665-B2 | Mutant IDH1 inhibitors | ELI LILLY AND COMPANY (US) | 2020-06-30 | — | — | US | disclosed |
| CN-107663190-B | Preparation method of nilapanib and intermediate thereof and intermediate compound | 钟桂发 | 2020-06-09 | — | — | CN | disclosed |
| US-10676456-B2 | Polycyclic amines as opioid receptor modulators | Ecstasy LLC | 2020-06-09 | — | — | US | disclosed |
| US-20200172480-A1 | CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2020-06-04 | — | — | US | disclosed |
| US-20200172480-A1 | CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2020-06-04 | — | — | US | disclosed |
| US-10611739-B2 | Process for preparation of lactone derivatives and intermediates thereof | PHARMARESOURCES (SHANGHAI) CO., LTD. (CN) | 2020-04-07 | — | — | US | disclosed |
| EP-3621652-A1 | A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | Hangzhou DAC Biotech Co, Ltd (CN) | 2020-03-18 | — | — | EP | disclosed |
| CN-110891938-A | Tetrahydro-benzo [ D ] azepin slow derivatives as GPR120 modulators | 卡尔丹治疗有限公司 | 2020-03-17 | — | — | CN | disclosed |
| US-20200071309-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | ISOCURE BIOSCIENCES INC (US) | 2020-03-05 | — | — | US | disclosed |
| US-20200071309-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | ISOCURE BIOSCIENCES INC (US) | 2020-03-05 | — | — | US | disclosed |
| EP-3601229-A1 | TETRAHYDRO-BENZO[D]AZEPINE DERIVATIVES AS GPR120 MODULATORS | Caldan Therapeutics Limited (GB) | 2020-02-05 | — | — | EP | disclosed |
| US-10550141-B2 | Tetradentate ligand, and production method therefor, synthetic intermediate thereof, and transition metal complex thereof | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2020-02-04 | — | — | US | disclosed |
| US-10550141-B2 | Tetradentate ligand, and production method therefor, synthetic intermediate thereof, and transition metal complex thereof | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2020-02-04 | — | — | US | disclosed |
| US-10550099-B2 | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| CN-110662541-A | Polycyclic amines as opioid receptor modulators | 王晓冬 | 2020-01-07 | — | — | CN | disclosed |
| EP-3194383-B1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS INC (US) | 2019-11-06 | — | — | EP | disclosed |
| EP-3030556-B1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | UNIV DARMSTADT TECH (DE) | 2019-10-30 | — | — | EP | disclosed |
| EP-3555079-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | Isocure Biosciences Inc. (US) | 2019-10-23 | — | — | EP | disclosed |
| CN-110357813-A | A kind of new indole amine 2,3- dioxygenase inhibitor and its preparation method and application | 信达生物制药(苏州)有限公司 | 2019-10-22 | — | — | CN | disclosed |
| WO-2019196780-A1 | NOVEL INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 信达生物制药(苏州)有限公司 | 2019-10-17 | — | — | WO | disclosed |
| US-10442798-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2019-10-15 | — | — | US | disclosed |
| US-10426135-B2 | Methyl- and trifluromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof | PFIZER INC. (US) | 2019-10-01 | — | — | US | disclosed |
| CN-110291085-A | Saltant type isocitric dehydrogenase inhibitor, composition and its method | 艾科生物科技有限公司 | 2019-09-27 | — | — | CN | disclosed |
| US-20190292175-A1 | MUTANT IDH1 INHIBITORS | ELI LILLY AND COMPANY | 2019-09-26 | — | — | US | disclosed |
| EP-3543229-A1 | METHOD FOR PREPARING OPTICALLY PURE (R)-4-N-PROPYL-DIHYDROFURAN-2(3H)-ONE | Beijing AblePharmtech Co., Ltd. (CN) | 2019-09-25 | — | — | EP | disclosed |
| US-10407419-B2 | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-10407419-B2 | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20190263779-A1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
| US-10385036-B2 | Sulfonamide-substituted indole modulators of RORC2 and methods of use thereof | PFIZER INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-10364237-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2019-07-30 | — | — | US | disclosed |
| CN-106715416-B | The pyrrolopyridine regulator and its application method that the methyl and trifluoromethyl of RORC2 replaces | 辉瑞大药厂 | 2019-07-23 | — | — | CN | disclosed |
| US-20190210995-A1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-20190210981-A1 | PROCESS FOR PREPARATION OF LACTONE DERIVATIVES AND INTERMEDIATES THEREOF | PHARMARESOURCES (SHANGHAI) CO., LTD. (CN) | 2019-07-11 | — | — | US | disclosed |
| US-10336748-B2 | Methyoxy-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof | PFIZER INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20190185443-A1 | Novel Cannabinergic Compounds And Uses Thereof | NORTHEASTERN UNIVERSITY | 2019-06-20 | — | — | US | disclosed |
| US-20190185443-A1 | Novel Cannabinergic Compounds And Uses Thereof | NORTHEASTERN UNIVERSITY | 2019-06-20 | — | — | US | disclosed |
| CN-109843860-A | Process for producing lactone derivative and intermediate thereof | 上海泓博智源医药股份有限公司 | 2019-06-04 | — | — | CN | disclosed |
| US-20190150401-A1 | Methyl- and Trifluromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof | PFIZER INC. (US) | 2019-05-23 | — | — | US | disclosed |
| US-20190127407-A1 | TETRADENTATE LIGAND, AND PRODUCTION METHOD THEREFOR, SYNTHETIC INTERMEDIATE THEREOF, AND TRANSITION METAL COMPLEX THEREOF | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2019-05-02 | — | — | US | disclosed |
| US-20190127407-A1 | TETRADENTATE LIGAND, AND PRODUCTION METHOD THEREFOR, SYNTHETIC INTERMEDIATE THEREOF, AND TRANSITION METAL COMPLEX THEREOF | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2019-05-02 | — | — | US | disclosed |
| EP-3464281-A1 | MUTANT IDH1 INHIBITORS | Eli Lilly and Company (US) | 2019-04-10 | — | — | EP | disclosed |
| US-10246413-B2 | Selective FKBP51 ligands for treatment of psychiatric disorders | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2019-04-02 | — | — | US | disclosed |
| US-10227346-B2 | Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use therof | PFIZER INC. (US) | 2019-03-12 | — | — | US | disclosed |
| EP-3438113-A1 | TETRADENTATE LIGAND, AND PRODUCTION METHOD THEREFOR, SYNTHETIC INTERMEDIATE THEREOF, AND TRANSITION METAL COMPLEX THEREOF | Takasago International Corporation (JP) | 2019-02-06 | — | — | EP | disclosed |
| US-20190031599-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | TAKEDA CAMBRIDGE LIMITED (GB) | 2019-01-31 | — | — | US | disclosed |
| EP-3408256-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | Takeda Pharmaceutical Company Limited (JP) | 2018-12-05 | — | — | EP | disclosed |
| EP-3406609-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC RECEPTOR AGONISTS | Heptares Therapeutics Limited (GB) | 2018-11-28 | — | — | EP | disclosed |
| US-10118920-B2 | Isoxazolyl substituted benzimidazoles | CELLCENTRIC LTD (GB) | 2018-11-06 | — | — | US | disclosed |
| WO-2018172727-A1 | TETRAHYDRO-BENZO[D]AZEPINE DERIVATIVES AS GPR120 MODULATORS | CALDAN THERAPEUTICS LIMITED (GB) | 2018-09-27 | — | — | WO | disclosed |
| US-20180273504-A1 | Sulfonamide-Substituted Indole Modulators of RORC2 and Methods of Use Thereof | PFIZER INC. (US) | 2018-09-27 | — | — | US | disclosed |
| US-20180265502-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | LYCERA CORPORATION | 2018-09-20 | — | — | US | disclosed |
| WO-2018169818-A1 | POLYCYCLIC AMINES AS OPIOID RECEPTOR MODULATORS | WANG XIAODONG (US) | 2018-09-20 | — | — | WO | disclosed |
| US-20180258065-A1 | POLYCYCLIC AMINES AS OPIOID RECEPTOR MODULATORS | Ecstasy LLC | 2018-09-13 | — | — | US | disclosed |
| EP-3371174-A1 | INDOLIN-2-ONE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2018-09-12 | — | — | EP | disclosed |
| US-20180251450-A1 | INDOLIN-2-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-09-06 | — | — | US | disclosed |
| US-20180242582-A1 | MACROCYCLIC PICOLINAMIDES AS FUNGICIDES | DOW AGROSCIENCES LLC (US) | 2018-08-30 | — | — | US | disclosed |
| US-20180208587-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | LYCERA CORPORATION | 2018-07-26 | — | — | US | disclosed |
| WO-2018118793-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | ISOCURE BIOSCIENCES INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| EP-3102568-B1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS. | HEPTARES THERAPEUTICS LTD (GB) | 2018-06-27 | — | — | EP | disclosed |
| US-20180170928-A1 | Methyl- and Trifluoromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof | PFIZER INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180134682-A1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180127402-A1 | ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES | CELLCENTRIC LTD (GB) | 2018-05-10 | — | — | US | disclosed |
| US-20180127402-A1 | ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES | CELLCENTRIC LTD (GB) | 2018-05-10 | — | — | US | disclosed |
| US-20180127402-A1 | ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES | CELLCENTRIC LTD (GB) | 2018-05-10 | — | — | US | disclosed |
| US-20180118732-A1 | QUINOLINONE FIVE-MEMBERED HETEROCYCLIC COMPOUNDS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2018-05-03 | — | — | US | disclosed |
| US-20180118732-A1 | QUINOLINONE FIVE-MEMBERED HETEROCYCLIC COMPOUNDS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2018-05-03 | — | — | US | disclosed |
| US-20180118732-A1 | QUINOLINONE FIVE-MEMBERED HETEROCYCLIC COMPOUNDS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2018-05-03 | — | — | US | disclosed |
| US-9957229-B2 | Amido compounds and their use as pharmaceuticals | INCYTE HOLDINGS CORPORATION (US) | 2018-05-01 | — | — | US | disclosed |
| US-9955691-B2 | Macrocyclic picolinamides as fungicides | DOW AGROSCIENCES LLC (US) | 2018-05-01 | — | — | US | disclosed |
| US-9955691-B2 | Macrocyclic picolinamides as fungicides | DOW AGROSCIENCES LLC (US) | 2018-05-01 | — | — | US | disclosed |
| US-9955691-B2 | Macrocyclic picolinamides as fungicides | DOW AGROSCIENCES LLC (US) | 2018-05-01 | — | — | US | disclosed |
| US-9920054-B2 | Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof | PFIZER INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20180072667-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | HAUSCH, FELIX (DE) | 2018-03-15 | — | — | US | disclosed |
| EP-3286183-A1 | ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES | Cellcentric Ltd (GB) | 2018-02-28 | — | — | EP | disclosed |
| WO-2018032356-A1 | PROCESS FOR PREPARATION OF LACTONE DERIVATIVES AND INTERMEDIATES THEREOF | PHARMARESOURCES (SHANGHAI) CO., LTD. (CN) | 2018-02-22 | — | — | WO | disclosed |
| US-9896441-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2018-02-20 | — | — | US | disclosed |
| EP-2927217-B1 | AMIDE COMPOUND AND PHARMACEUTICAL APPLICATION THEREFOR | JAPAN TOBACCO INC (JP) | 2018-01-17 | — | — | EP | disclosed |
| US-20180002330-A1 | Methyoxy-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof | PFIZER INC. (US) | 2018-01-04 | — | — | US | disclosed |
| US-9845292-B2 | Selective FKBP51 ligands for treatment of psychiatric disorders | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-12-19 | — | — | US | disclosed |
| US-9845299-B2 | Process for the preparation of a fluorolacton derivative | GILEAD PHARMASSET LLC (US) | 2017-12-19 | — | — | US | disclosed |
| US-9845299-B2 | Process for the preparation of a fluorolacton derivative | GILEAD PHARMASSET LLC (US) | 2017-12-19 | — | — | US | disclosed |
| US-9845299-B2 | Process for the preparation of a fluorolacton derivative | GILEAD PHARMASSET LLC (US) | 2017-12-19 | — | — | US | disclosed |
| WO-2017213910-A1 | MUTANT IDH1 INHIBITORS | ELI LILLY AND COMPANY (US) | 2017-12-14 | — | — | WO | disclosed |
| EP-3250237-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | Sutro Biopharma, Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-3250570-A1 | METHOXY-SUBSTITUTED PYRROLOPYRIDINE MODULATORS OF RORC2 AND METHODS OF USE THEREOF | Pfizer Inc (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-3250561-A1 | SULFONAMIDE-SUBSITUTED INDOLE MODULATORS OF RORC2 AND METHODS OF USE THEREOF | Pfizer Inc (US) | 2017-12-06 | — | — | EP | disclosed |
| CN-107428801-A | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | 苏特罗生物制药公司 | 2017-12-01 | — | — | CN | disclosed |
| US-20170334847-A1 | Amido Compounds And Their Use As Pharmaceuticals | INCYTE CORPORATION | 2017-11-23 | — | — | US | disclosed |
| US-9815817-B2 | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815817-B2 | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| EP-2943475-B1 | PROCESS FOR THE PREPARATION OF A FLUOROLACTON DERIVATIVE | GILEAD PHARMASSET LLC (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2943475-B1 | PROCESS FOR THE PREPARATION OF A FLUOROLACTON DERIVATIVE | GILEAD PHARMASSET LLC (US) | 2017-10-25 | — | — | EP | disclosed |
| CN-107216312-A | A kind of compound with saltant type IDH inhibitory activity, preparation method and the usage | 上海海和药物研究开发有限公司 | 2017-09-29 | — | — | CN | disclosed |
| WO-2017140758-A1 | DERIVATIVES OF 2-AMINO-4-(2-OXAZOLIDINON-3-YL)-PYRIMIDINE FUSED WITH A FIVE-MEMBERED HETEROAROMATIC RING IN 5,6-POSITION WHICH ARE USEFUL FOR THE TREATMENT OF VARIOUS CANCERS | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2017-08-24 | — | — | WO | disclosed |
| US-20170233390-A1 | Methyl- and Trifluoromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof | PFIZER INC. (US) | 2017-08-17 | — | — | US | disclosed |
| WO-2017131221-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-03 | — | — | WO | disclosed |
| EP-3197882-A1 | METHYL-AND TRIFLUOROMETHYL-SUBSTITUTED PYRROLOPYRIDINE MODULATORS OF RORC2 AND METHODS OF USE THEREOF | Pfizer Inc (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-2771337-B1 | 3-(PYRIMIDIN-4-YL)-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016120850-A9 | SULFONAMIDE-SUBSITUTED INDOLE MODULATORS OF RORC2 AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2017-07-20 | — | — | WO | disclosed |
| US-20170183331-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-06-29 | — | — | US | disclosed |
| US-20170183317-A1 | PROCESS FOR THE PREPARATION OF A FLUOROLACTION DERIVATIVE | GILEAD SCIENCES, INC. | 2017-06-29 | — | — | US | disclosed |
| US-20170183317-A1 | PROCESS FOR THE PREPARATION OF A FLUOROLACTION DERIVATIVE | GILEAD SCIENCES, INC. | 2017-06-29 | — | — | US | disclosed |
| US-20170183317-A1 | PROCESS FOR THE PREPARATION OF A FLUOROLACTION DERIVATIVE | GILEAD SCIENCES, INC. | 2017-06-29 | — | — | US | disclosed |
| US-9670201-B2 | Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof | PFIZER INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670154-B2 | Amido compounds and their use as pharmaceuticals | INCYTE HOLDINGS CORPORATION (US) | 2017-06-06 | — | — | US | disclosed |
| CN-106715416-A | Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof | 辉瑞大药厂 | 2017-05-24 | — | — | CN | disclosed |
| EP-3166936-A1 | MACROCYCLIC PICOLINAMIDES AS FUNGICIDES | Dow AgroSciences LLC (US) | 2017-05-17 | — | — | EP | disclosed |
| US-9650362-B2 | Inhibitors | PROBIODRUG AG (DE) | 2017-05-16 | — | — | US | disclosed |
| WO-2017076842-A1 | INDOLIN-2-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-05-11 | — | — | WO | disclosed |
| US-9624183-B2 | Process for the preparation of a fluorolacton derivative | GILEAD PHARMASSET LLC (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624216-B2 | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624183-B2 | Process for the preparation of a fluorolacton derivative | GILEAD PHARMASSET LLC (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624216-B2 | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624183-B2 | Process for the preparation of a fluorolacton derivative | GILEAD PHARMASSET LLC (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624216-B2 | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| EP-2897938-B1 | FLUOROALKYL DIBENZODIAZEPINONE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-03-15 | — | — | EP | disclosed |
| US-20170015710-A1 | CYCLIC PEPTIDE ANALOGS AND CONJUGATES THEREOF | SIRENAS LLC (US) | 2017-01-19 | — | — | US | disclosed |
| US-20170007686-A1 | Adoptive Cellular Therapy Using an Agonist of Retinoic Acid Receptor-Related Orphan Receptor Gamma & Related Therapeutic Methods | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-01-12 | — | — | US | disclosed |
| EP-2897945-B1 | BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS AS NOTCH INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-21 | — | — | EP | disclosed |
| US-20160346256-A1 | AMIDE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2016-12-01 | — | — | US | disclosed |
| EP-2897946-B1 | N-SUBSTITUTED BIS(FLUOROALKKYL)-1,4-BENZODIAZEPINONE COMPOUNDS AS NOTCH INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-16 | — | — | EP | disclosed |
| EP-2941427-B1 | NOVEL BENZODIOXANE-PIPERIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | PF MEDICAMENT (FR) | 2016-11-09 | — | — | EP | disclosed |
| WO-2016170324-A1 | ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES | CELLCENTRIC LTD (GB) | 2016-10-27 | — | — | WO | disclosed |
| WO-2016170324-A1 | ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES | CELLCENTRIC LTD (GB) | 2016-10-27 | — | — | WO | disclosed |
| US-20160311818-A1 | QUINOLINONE FIVE-MEMBERED HETEROCYCLIC COMPOUNDS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-10-27 | — | — | US | disclosed |
| US-20160311818-A1 | QUINOLINONE FIVE-MEMBERED HETEROCYCLIC COMPOUNDS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-10-27 | — | — | US | disclosed |
| US-20160311818-A1 | QUINOLINONE FIVE-MEMBERED HETEROCYCLIC COMPOUNDS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-10-27 | — | — | US | disclosed |
| EP-2897947-B1 | ALKYL, FLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-2897944-B1 | SUBSTITUTED 1,5-BENZODIAZEPINONE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20160289184-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | HAUSCH, FELIX (DE) | 2016-10-06 | — | — | US | disclosed |
| WO-2016120849-A9 | METHOXY-SUBSTITUTED PYRROLOPYRIDINE MODULATORS OF RORC2 AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2016-09-29 | — | — | WO | disclosed |
| US-20160257709-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160257709-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. | 2016-09-08 | — | — | US | disclosed |
| EP-2897941-B1 | PRODRUGS OF 1,4-BENZODIAZEPINONE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2016-09-07 | — | — | EP | disclosed |
| EP-2897942-B1 | FLUOROALKYL AND FLUOROCYCLOALKYL 1,4-BENZODIAZEPINONE COMPOUNDS AS NOTCH INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-31 | — | — | EP | disclosed |
| US-9427442-B2 | Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-30 | — | — | US | disclosed |
| WO-2016120850-A1 | SULFONAMIDE-SUBSITUTED INDOLE MODULATORS OF RORC2 AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2016-08-04 | — | — | WO | disclosed |
| WO-2016123582-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
| WO-2016123582-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
| WO-2016120849-A1 | METHOXY-SUBSTITUTED PYRROLOPYRIDINE MODULATORS OF RORC2 AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2016-08-04 | — | — | WO | disclosed |
| EP-2897960-B1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS NOTCH INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-03 | — | — | EP | disclosed |
| EP-2776404-B1 | HETEROCYCLIC ANALOGS OF PROPARGYL-LINKED INHIBITORS OF DIHYDROFOLATE REDUCTASE | UNIV CONNECTICUT (US) | 2016-07-06 | — | — | EP | disclosed |
| EP-3030556-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften (DE) | 2016-06-15 | — | — | EP | disclosed |
| CN-105638692-A | Pesticide for liriomyza huidobrensis | 烟台顺隆化工科技有限公司 | 2016-06-08 | — | — | CN | disclosed |
| CN-105638692-A | Pesticide for liriomyza huidobrensis | 烟台顺隆化工科技有限公司 | 2016-06-08 | — | — | CN | disclosed |
| US-20160137639-A1 | TRIAZOLE-ISOXAZOLE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2016-05-19 | — | — | US | disclosed |
| US-20160108016-A1 | Novel Cannabinergic Compounds and Uses Thereof | NORTHEASTERN UNIVERSITY (US) | 2016-04-21 | — | — | US | disclosed |
| US-20160108016-A1 | Novel Cannabinergic Compounds and Uses Thereof | NORTHEASTERN UNIVERSITY (US) | 2016-04-21 | — | — | US | disclosed |
| US-20160102058-A1 | FLUORO-PERHEXILINE COMPOUNDS AND THEIR THERAPEUTIC USE | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2016-04-14 | — | — | US | disclosed |
| US-20160090381-A1 | Methyl- and Trifluoromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof | PFIZER (US) | 2016-03-31 | — | — | US | disclosed |
| WO-2016046755-A1 | METHYL-AND TRIFLUOROMETHYL-SUBSTITUTED PYRROLOPYRIDINE MODULATORS OF RORC2 AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016044781-A1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20160083365-A1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20160083365-A1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-03-24 | — | — | US | disclosed |
| EP-2997012-A1 | FLUORO-PERHEXILINE COMPOUNDS AND THEIR THERAPEUTIC USE | The University Court of The University of Aberdeen (GB) | 2016-03-23 | — | — | EP | disclosed |
| US-20160060232-A1 | BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2016-03-03 | — | — | US | disclosed |
| US-9273075-B2 | Prodrugs of 1,4-benzodiazepinone compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273014-B2 | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds and prodrugs thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| US-20160039795-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2016-02-11 | — | — | US | disclosed |
| US-9249157-B2 | Tricyclic heterocycle compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-02 | — | — | US | disclosed |
| US-9242941-B2 | Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-26 | — | — | US | disclosed |
| US-9242940-B2 | N-substituted bis(fluoroalkyl)-1,4-benzodiazepinone compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-26 | — | — | US | disclosed |
| US-20160007601-A1 | MACROCYCLIC PICOLINAMIDES AS FUNGICIDES | DOW AGROSCIENCES LLC | 2016-01-14 | — | — | US | disclosed |
| US-20160007601-A1 | MACROCYCLIC PICOLINAMIDES AS FUNGICIDES | DOW AGROSCIENCES LLC | 2016-01-14 | — | — | US | disclosed |
| US-20160007601-A1 | MACROCYCLIC PICOLINAMIDES AS FUNGICIDES | DOW AGROSCIENCES LLC | 2016-01-14 | — | — | US | disclosed |
| WO-2016007529-A1 | MACROCYCLIC PICOLINAMIDES AS FUNGICIDES | DOW AGROSCIENCES LLC (US) | 2016-01-14 | — | — | WO | disclosed |
| WO-2016007529-A1 | MACROCYCLIC PICOLINAMIDES AS FUNGICIDES | DOW AGROSCIENCES LLC (US) | 2016-01-14 | — | — | WO | disclosed |
| EP-2963021-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Holdings Corporation (US) | 2016-01-06 | — | — | EP | disclosed |
| US-9199959-B2 | HIV replication inhibitor | SHIONOGI & CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-9199959-B2 | HIV replication inhibitor | SHIONOGI & CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20150336943-A1 | NOVEL BENZODIOXANE-PIPERIDINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS FOR TREATING NEUROPSYCHIATRIC DISORDERS | PIERRE FABRE MEDICAMENT (FR) | 2015-11-26 | — | — | US | disclosed |
| US-20150329561-A1 | Amido Compounds And Their Use As Pharmaceuticals | INCYTE CORPORATION | 2015-11-19 | — | — | US | disclosed |
| EP-2943475-A1 | PROCESS FOR THE PREPARATION OF A FLUOROLACTON DERIVATIVE | F. Hoffmann-La Roche AG (CH) | 2015-11-18 | — | — | EP | disclosed |
| US-9187434-B2 | Substituted 1,5-benzodiazepinones compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-17 | — | — | US | disclosed |
| EP-2941427-A1 | NOVEL BENZODIOXANE-PIPERIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | Pierre Fabre Médicament (FR) | 2015-11-11 | — | — | EP | disclosed |
| US-20150315165-A1 | PROCESS FOR THE PREPARATION OF A FLUOROLACTON DERIVATIVE | HOFFMANN-LA ROCHE INC. (US) | 2015-11-05 | — | — | US | disclosed |
| US-20150315165-A1 | PROCESS FOR THE PREPARATION OF A FLUOROLACTON DERIVATIVE | HOFFMANN-LA ROCHE INC. (US) | 2015-11-05 | — | — | US | disclosed |
| US-20150315165-A1 | PROCESS FOR THE PREPARATION OF A FLUOROLACTON DERIVATIVE | HOFFMANN-LA ROCHE INC. (US) | 2015-11-05 | — | — | US | disclosed |
| US-9173885-B2 | Inhibitors | PROBIODRUG AG (DE) | 2015-11-03 | — | — | US | disclosed |
| US-20150284342-A1 | BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2015-10-08 | — | — | US | disclosed |
| EP-2927217-A1 | Amide compound and pharmaceutical application therefor | Japan Tobacco Inc. (JP) | 2015-10-07 | — | — | EP | disclosed |
| US-20150274679-A1 | SUBSTITUTED 1,5-BENZODIAZEPINONES COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2015-10-01 | — | — | US | disclosed |
| US-9133126-B2 | Fluoroalkyl dibenzoazepinone compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-15 | — | — | US | disclosed |
| CN-103619824-B | Amide compound and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2015-09-09 | — | — | CN | disclosed |
| US-9126927-B2 | Amido compounds and their use as pharmaceuticals | INCYTE HOLDINGS CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150246892-A1 | N-SUBSTITUTED BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2015-09-03 | — | — | US | disclosed |
| US-20150246930-A1 | TRICYCLIC HETEROCYCLE COMPOUNDS | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2015-09-03 | — | — | US | disclosed |
| US-20150239851-A1 | ALKYL, FLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS | BRISTOL-METERS SQUIBB COMPANY (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150231152-A1 | FLUOROALKYL AND FLUOROCYCLOALKYL 1,4-BENZODIAZEPINONE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2015-08-20 | — | — | US | disclosed |
| US-20150232491-A1 | PRODRUGS OF 1,4-BENZODIAZEPINONE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2015-08-20 | — | — | US | disclosed |
| US-20150218104-A1 | FLUOROALKYL DIBENZOAZEPINONE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2015-08-06 | — | — | US | disclosed |
| EP-2897945-A1 | BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS AS NOTCH INHIBITORS | Bristol-Myers Squibb Company (US) | 2015-07-29 | — | — | EP | disclosed |
| EP-2897938-A1 | FLUOROALKYL DIBENZODIAZEPINONE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2015-07-29 | — | — | EP | disclosed |
| EP-2897960-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS NOTCH INHIBITORS | Bristol-Myers Squibb Company (US) | 2015-07-29 | — | — | EP | disclosed |
| EP-1756063-B1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2015-07-08 | — | — | EP | disclosed |
| EP-2475428-B1 | HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2015-07-01 | — | — | EP | disclosed |
| US-9062007-B2 | Cyclic amide BACE-1 inhibitors having a benzamide substituent | MERCK SHARP & DOHME CORP. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150166489-A1 | BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS AND PRODRUGS THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2015-06-18 | — | — | US | disclosed |
| EP-2507210-B1 | CYCLOHEXANE DERIVATIVES AS INHIBITORS OF ACETYL-COA CARBOXYLASE (ACC) | NOVARTIS AG (CH) | 2015-04-08 | — | — | EP | disclosed |
| US-8999918-B2 | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds and prodrugs thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-07 | — | — | US | disclosed |
| WO-2015039758-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-03-26 | — | — | WO | disclosed |
| US-20150072942-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| US-8957068-B2 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | NOVARTIS AG (CH) | 2015-02-17 | — | — | US | disclosed |
| EP-2688873-B1 | BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2015-01-21 | — | — | EP | disclosed |
| US-20140357605-A1 | BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2014-12-04 | — | — | US | disclosed |
| WO-2014184561-A1 | FLUORO-PERHEXILINE COMPOUNDS AND THEIR THERAPEUTIC USE | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2014-11-20 | — | — | WO | disclosed |
| US-8865726-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140309174-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD (JP) | 2014-10-16 | — | — | US | disclosed |
| US-20140309174-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD (JP) | 2014-10-16 | — | — | US | disclosed |
| US-8853228-B2 | Heterocyclic analogs of propargyl-linked inhibitors of dihydrofolate reductase | UNIVERSITY OF CONNECTICUT (US) | 2014-10-07 | — | — | US | disclosed |
| US-20140296306-A1 | AMIDE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2014-10-02 | — | — | US | disclosed |
| EP-2776404-A1 | HETEROCYCLIC ANALOGS OF PROPARGYL-LINKED INHIBITORS OF DIHYDROFOLATE REDUCTASE | University of Connecticut (US) | 2014-09-17 | — | — | EP | disclosed |
| US-20140249306-A1 | HIV REPLICATION INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2014-09-04 | — | — | US | disclosed |
| US-20140249306-A1 | HIV REPLICATION INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2014-09-04 | — | — | US | disclosed |
| EP-2771337-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | Novartis AG (CH) | 2014-09-03 | — | — | EP | disclosed |
| US-8822454-B2 | Bisfluoroalkyl-1,4-benzodiazepinone compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140235620-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2014-08-21 | — | — | US | disclosed |
| CN-103958506-A | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | NOVARTIS AG | 2014-07-30 | — | — | CN | disclosed |
| WO-2014108525-A1 | PROCESS FOR THE PREPARATION OF A FLUOROLACTON DERIVATIVE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-07-17 | — | — | WO | disclosed |
| WO-2014108525-A1 | PROCESS FOR THE PREPARATION OF A FLUOROLACTON DERIVATIVE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-07-17 | — | — | WO | disclosed |
| WO-2014106660-A1 | NOVEL BENZODIOXANE-PIPERIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | PIERRE FABRE MEDICAMENT (FR) | 2014-07-10 | — | — | WO | disclosed |
| US-20140128361-A1 | CYCLIC AMIDE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-8703947-B2 | Compounds for treatment of Alzheimer's disease | PURDUE RESEARCH FOUNDATION (US) | 2014-04-22 | — | — | US | disclosed |
| EP-2719690-A1 | AMIDE COMPOUND AND PHARMACEUTICAL APPLICATION THEREFOR | Japan Tobacco Inc. (JP) | 2014-04-16 | — | — | EP | disclosed |
| US-20140100365-A1 | BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-04-10 | — | — | US | disclosed |
| WO-2014047372-A1 | BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS AS NOTCH INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-27 | — | — | WO | disclosed |
| US-20140087992-A1 | BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS AND PRODRUGS THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2014-03-27 | — | — | US | disclosed |
| WO-2014047370-A1 | FLUOROALKYL DIBENZODIAZEPINONE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-27 | — | — | WO | disclosed |
| WO-2014047390-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS NOTCH INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-27 | — | — | WO | disclosed |
| WO-2014039042-A1 | NOVEL CANNABINERGIC COMPOUNDS AND USES THEREOF | NORTHEASTERN UNIVERSITY (US) | 2014-03-13 | — | — | WO | disclosed |
| US-20140065095-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2014-03-06 | — | — | US | disclosed |
| EP-2558449-B1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-03-05 | — | — | EP | disclosed |
| CN-103619824-A | Amide compound and pharmaceutical application therefor | JAPAN TOBACCO INC | 2014-03-05 | — | — | CN | disclosed |
| US-8633224-B2 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | EISAI CO., LTD. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-8633224-B2 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | EISAI CO., LTD. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-8629136-B2 | Bisfluoroalkyl-1,4-benzodiazepinone compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-14 | — | — | US | disclosed |
| US-8623867-B2 | Cyclic amine BACE-1 inhibitors having a benzamide substituent | MERCK SHARP & DOHME CORP. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8604069-B2 | Amide compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2013-12-10 | — | — | US | disclosed |
| US-20130310320-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-8586747-B2 | 3,3-dimethyl tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130184313-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-07-18 | — | — | US | disclosed |
| US-8486940-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-07-16 | — | — | US | disclosed |
| EP-2364975-B1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-06-12 | — | — | EP | disclosed |
| US-8445684-B2 | Nicotinic acetylcholine receptor ligands and the uses thereof | PsycoGenics Inc. (US) | 2013-05-21 | — | — | US | disclosed |
| WO-2013070620-A1 | HETEROCYCLIC ANALOGS OF PROPARGYL-LINKED INHIBITORS OF DIHYDROFOLATE REDUCTASE | UNIVERSITY OF CONNECTICUT (US) | 2013-05-16 | — | — | WO | disclosed |
| US-8435983-B2 | Conformationally restrained epothilone analogues as anti-leukemic agents | THE UNIVERSITY OF TOLEDO (US) | 2013-05-07 | — | — | US | disclosed |
| US-20130102593-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2013-04-25 | — | — | US | disclosed |
| US-8426432-B2 | Inhibitors of dihydrofolate reductase with antibacterial antiprotozoal, antifungal and anticancer properties | UNIVERSITY OF CONNECTICUT (US) | 2013-04-23 | — | — | US | disclosed |
| WO-2013046136-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2013-04-04 | — | — | WO | disclosed |
| US-8394858-B2 | Cyclohexane derivatives and uses thereof | NOVARTIS AG (CH) | 2013-03-12 | — | — | US | disclosed |
| US-20130059840-A1 | SULFONAMIDO PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| EP-2558449-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2013-02-20 | — | — | EP | disclosed |
| US-8378099-B2 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACUETICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20130023518-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | Hoffmann-La Roche Inc (US) | 2013-01-24 | — | — | US | disclosed |
| US-8357524-B2 | Chemically modified mutant serine hydrolases show improved catalytic activity and chiral selectivity | DANISCO US INC. (US) | 2013-01-22 | — | — | US | disclosed |
| US-8354401-B2 | Oxazolidinone amide aromatic compounds for supressing MMP-9 production | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-01-15 | — | — | US | disclosed |
| US-20130004518-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | Merck, Sharp & Dohme Corp. (US) | 2013-01-03 | — | — | US | disclosed |
| US-8344137-B2 | 3,3-dimethyl tetrahydroquinoline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120322837-A1 | AMIDE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2012-12-20 | — | — | US | disclosed |
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| US-20120295894-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BILCER GEOFFREY M (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295329-A1 | CHEMICALLY MODIFIED MUTANT SERINE HYDROLASES SHOW IMPROVED CATALYTIC ACTIVITY AND CHIRAL SELECTIVITY | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2012-11-22 | — | — | US | disclosed |
| EP-2507210-A1 | CYCLOHEXANE DERIVATIVES AS INHIBITORS OF ACETYL-COA CARBOXYLASE (ACC) | Novartis AG (CH) | 2012-10-10 | — | — | EP | disclosed |
| US-8278334-B2 | Cyclic amine BACE-1 inhibitors having a benzamide substituent | Merck, Sharp & Dohme Corp. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20120245151-A1 | BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-27 | — | — | US | disclosed |
| US-20120214802-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2012-08-23 | — | — | US | disclosed |
| EP-2486006-A1 | SULFONAMIDO PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2012-08-15 | — | — | EP | disclosed |
| US-20120196859-A1 | HETEROCYCLIC ANALOGS OF PROPARGYL-LINKED INHIBITORS OF DIHYDROFOLATE REDUCTASE | UNIVERSITY OF CONNECTICUT | 2012-08-02 | — | — | US | disclosed |
| US-8232271-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-07-31 | — | — | US | disclosed |
| EP-2475428-A1 | HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2012-07-18 | — | — | EP | disclosed |
| US-20120178715-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-8212065-B2 | Method for the production of optically active alpha alkyl carbonyl compounds | ALBERT-LUDWIGS-UNIVERSITAT FREIBURG (DE) | 2012-07-03 | — | — | US | disclosed |
| US-20120156721-A1 | CHEMICALLY MODIFIED MUTANT SERINE HYDROLASES SHOW IMPROVED CATALYTIC ACTIVITY AND CHIRAL SELECTIVITY | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2012-06-21 | — | — | US | disclosed |
| US-8148128-B2 | Chemically modified mutant serine hydrolases show improved catalytic activity and chiral selectivity | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2012-04-03 | — | — | US | disclosed |
| US-8129407-B2 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | EISAI INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129407-B2 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | EISAI INC. (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2411000-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20120015928-A1 | Amido Compounds And Their Use As Pharmaceuticals | INCYTE CORPORATION (US) | 2012-01-19 | — | — | US | disclosed |
| US-20110306560-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-8067379-B2 | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067379-B2 | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067379-B2 | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2011-11-29 | — | — | US | disclosed |
| US-8058288-B2 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2011-11-15 | — | — | US | disclosed |
| EP-1730110-B9 | SULFUR COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORP (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-1730110-B9 | SULFUR COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORP (US) | 2011-11-02 | — | — | EP | disclosed |
| US-20110263571-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| WO-2011130383-A1 | COMPOUNDS CONTAINING FUSED RINGS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011128251-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-20 | — | — | WO | disclosed |
| US-20110257151-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | HUA MEDICINE (KY) | 2011-10-20 | — | — | US | disclosed |
| EP-2364975-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-8017779-B2 | Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-09-13 | — | — | US | disclosed |
| US-8003791-B2 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20110195978-A1 | COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE | PURDUE RESEARCH FOUNDATION (US) | 2011-08-11 | — | — | US | disclosed |
| CN-101287738-B | Imidazo benzodiazepine derivatives | HOFFMANN LA ROCHE | 2011-08-10 | — | — | CN | disclosed |
| EP-2350007-A1 | HETEROCYCLIC ANTIVIRAL ARYLPYRIDONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-08-03 | — | — | EP | disclosed |
| EP-2349308-A1 | COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE | Purdue Research Foundation (US) | 2011-08-03 | — | — | EP | disclosed |
| EP-2349244-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20110136735-A1 | CYCLOHEXANE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2011-06-09 | — | — | US | disclosed |
| WO-2011067306-A1 | CYCLOHEXANE DERIVATIVES AS INHIBITORS OF ACETYL-COA CARBOXYLASE (ACC) | NOVARTIS AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| EP-2190809-B1 | METHOD FOR THE PRODUCTION OF OPTICALLY ACTIVE ALPHA ALKYL CARBONYL COMPOUNDS | UNIV ALBERT LUDWIGS FREIBURG (DE) | 2011-06-08 | — | — | EP | disclosed |
| US-20110092501-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-04-21 | — | — | US | disclosed |
| WO-2011044057-A1 | SULFONAMIDO PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| US-7910590-B2 | Cyclic amine bace-1 inhibitors having a heterocyclic substituent | SCHERING CORPORATION (US) | 2011-03-22 | — | — | US | disclosed |
| WO-2011029920-A1 | HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011029027-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| US-7893268-B2 | Epithiolone analogues | UNIVERSITY OF TOLEDO (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893268-B2 | Epithiolone analogues | UNIVERSITY OF TOLEDO (US) | 2011-02-22 | — | — | US | disclosed |
| US-7879911-B2 | 2-(4-Fluorophenoxy-N-hydroxyacetamide where the \"oxy\" can also be sulfonyl, sulfamyl or sulfinyl; enzyme inhibitors of the \"lethal factor\" enzyme released by bacillus anthraci that splits an essential peptide needed by mammals for signal transmission; antidotes; biological warfare | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-01 | — | — | US | disclosed |
| CN-101077875-B | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARM INC | 2011-01-26 | — | — | CN | disclosed |
| EP-2081890-B1 | ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-01-12 | — | — | EP | disclosed |
| EP-2081890-B1 | ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-20100324094-A1 | Conformationally Restrained Epothilone Analogues as Anti-Leukemic Agents | THE UNIVERSITY OF TOLEDO (US) | 2010-12-23 | — | — | US | disclosed |
| US-7855294-B2 | Cycloalkanopyridine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-7855294-B2 | Cycloalkanopyridine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-7855294-B2 | Cycloalkanopyridine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20100305352-A1 | METHOD FOR THE PRODUCTION OF OPTICALLY ACTIVE ALPHA ALKYL CARBONYL COMPOUNDS | ALBERT-LUDWIGS-UNIVERSITAT FREIBURG (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100256114-A1 | Amido Compounds And Their Use As Pharmaceuticals | INCYTE CORPORATION (US) | 2010-10-07 | — | — | US | disclosed |
| WO-2010110817-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| US-7776874-B2 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776910-B2 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776910-B2 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776910-B2 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC (US) | 2010-08-17 | — | — | US | disclosed |
| EP-1937688-B1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | disclosed |
| US-7772397-B2 | Biologically active peptides and compositions, their use | UNIVERSITY OF BRITISH COLUMBIA (CA) | 2010-08-10 | — | — | US | disclosed |
| US-20100152450-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | PSYCHOGENICS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152138-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | SCHERING CORP. | 2010-06-17 | — | — | US | disclosed |
| EP-1730110-B1 | SULFUR COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORP (US) | 2010-06-09 | — | — | EP | disclosed |
| EP-1730110-B1 | SULFUR COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORP (US) | 2010-06-09 | — | — | EP | disclosed |
| US-20100111900-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC | 2010-05-06 | — | — | US | disclosed |
| WO-2010049331-A1 | HETEROCYCLIC ANTIVIRAL ARYLPYRIDONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010042892-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010042796-A1 | COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE | PURDUE RESEARCH FOUNDATION (US) | 2010-04-15 | — | — | WO | disclosed |
| US-20100063095-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063095-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-7662816-B2 | Cyclic amine BACE-1 inhibitors having a benzamide substituent | SCHERING CORPORATION (US) | 2010-02-16 | — | — | US | disclosed |
| CN-101619057-A | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARM INC | 2010-01-06 | — | — | CN | disclosed |
| US-20090312341-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORPORATION | 2009-12-17 | — | — | US | disclosed |
| US-7626023-B2 | Compounds for treating tumors | WYETH (US) | 2009-12-01 | — | — | US | disclosed |
| US-7618978-B2 | Amides as BACE inhibitors | ELI LILLY AND COMPANY (US) | 2009-11-17 | — | — | US | disclosed |
| US-7618978-B2 | Amides as BACE inhibitors | ELI LILLY AND COMPANY (US) | 2009-11-17 | — | — | US | disclosed |
| CN-101573332-A | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | HOFFMANN LA ROCHE (CH) | 2009-11-04 | — | — | CN | disclosed |
| US-20090264487-A1 | HEMIASTERLIN ANALOGS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2009-10-22 | — | — | US | disclosed |
| US-20090258904-A1 | Epithiolone Analogues | UNIVERSITY OF TOLEDO | 2009-10-15 | — | — | US | disclosed |
| US-20090258904-A1 | Epithiolone Analogues | UNIVERSITY OF TOLEDO | 2009-10-15 | — | — | US | disclosed |
| EP-1650182-B1 | BRANCHED CARBOXYLIC ACID COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2009-10-07 | — | — | EP | disclosed |
| US-7598250-B2 | Cyclic amine BACE-1 inhibitors having a heterocyclic substituent | SCHERING CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090247731-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-7585885-B2 | Pyrrolidine derivatives useful as BACE inhibitors | ELI LILLY AND COMPANY (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585976-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-7585976-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-7579375-B2 | Branched carboxylic acid compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-08-25 | — | — | US | disclosed |
| US-7579323-B1 | Analogs of hemiasterlin wherein the indole moiety of hemiasterlin has been deleted or replaced demonstrate potent anti-mitotic and cytotoxic activity; may be useful in treatment of colon, breast, lung cancers | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2009-08-25 | — | — | US | disclosed |
| EP-2081890-A1 | ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2009-07-29 | — | — | EP | disclosed |
| EP-1492761-B1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WARNER LAMBERT CO (US) | 2009-07-22 | — | — | EP | disclosed |
| CN-100509804-C | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARM INC (US) | 2009-07-08 | — | — | CN | disclosed |
| EP-2069313-A2 | METALLOPROTEASE INHIBITORS | Alantos Pharmaceuticals Holdings, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-1129180-B1 | CHEMICALLY MODIFIED MUTANT SERINE HYDROLASES | UNIV TORONTO (CA) | 2009-06-10 | — | — | EP | disclosed |
| US-7538222-B2 | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARMACEUTICALS, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7531526-B2 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-7528152-B2 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2009-05-05 | — | — | US | disclosed |
| US-7528152-B2 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2009-05-05 | — | — | US | disclosed |
| US-20090105287-A1 | Inhibitors of Dihydrofolate Reductase With Antibacterial Antiprotozoal, Antifungal and Anticancer Properties | UNIVERSITY OF CONNECTICUT (US) | 2009-04-23 | — | — | US | disclosed |
| US-7517909-B2 | Amino acids with affinity for the α2δ-protein | PFIZER INC (US) | 2009-04-14 | — | — | US | disclosed |
| US-20090088573-A1 | BIOLOGICALLY ACTIVE PEPTIDES AND COMPOSITIONS, THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2009-04-02 | — | — | US | disclosed |
| EP-1756063-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2009-03-25 | — | — | EP | disclosed |
| US-7507729-B2 | for the treatment of cognitive disorders, anxiety, schizophrenia, and Alzheimer's disease; ligands; GABA A alpha 5 receptor inhibitors; 3-bromo-10-chloro-6-(2-oxo-pyrrolidin-1-ylmethyl)-9H-imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-20090075329-A1 | CHEMICALLY MODIFIED MUTANT SERINE HYDROLASES SHOW IMPROVED CATALYTIC ACTIVITY AND CHIRAL SELECTIVITY | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2009-03-19 | — | — | US | disclosed |
| EP-1660443-B1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | SCHERING CORP (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2009025919-A2 | 5-PROPARGYL-PYRIMIDINE DERIVATIVES AS INHIBITORS OF DIHYDROFOLATE REDUCTASE WITH ANTIBACTERIAL ANTIPROTOZOAL, ANTIFUNGAL AND ANTICANCER PROPERTIES | UNIVERSITY OF CONNECTICUT (US) | 2009-02-26 | — | — | WO | disclosed |
| US-20090023801-A1 | INHIBITORS OF BETA AMYLOID PRODUCTION | WYETH (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023801-A1 | INHIBITORS OF BETA AMYLOID PRODUCTION | WYETH (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023903-A1 | PROCESS FOR THE PREPARATION OF TRIFLUOROALKYL-PHENYL AND HETEROCYCLIC SULFONAMIDES | WYETH (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023903-A1 | PROCESS FOR THE PREPARATION OF TRIFLUOROALKYL-PHENYL AND HETEROCYCLIC SULFONAMIDES | WYETH (US) | 2009-01-22 | — | — | US | disclosed |
| WO-2009012205-A1 | INHIBITORS OF BETA AMYLOID PRODUCTION | WYETH (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009012201-A2 | PROCESS FOR THE PREPARATION OF TRIFLUOROALKYL-PHENYL AND HETEROCYCLIC SULFONAMIDES | WYETH (US) | 2009-01-22 | — | — | WO | disclosed |
| US-20090018342-A1 | NEW EPOTHIOLONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR PHARMACEUTICAL USE | KLAR ULRICH | 2009-01-15 | — | — | US | disclosed |
| WO-2009008905-A1 | HYDROXAMIC ACID DERIVATIVES OF PHENOXY-ACETIC ACIDS AND ANALOGS USEFUL AS THERAPEUTIC AGENTS FOR TREATING ANTHRAX POISONING | PANTHERA BIOPHARMA, LLC. | 2009-01-15 | — | — | WO | disclosed |
| US-7476682-B2 | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARMACEUTICALS, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| EP-1040119-B1 | HEMIASTERLIN ANALOGS | UNIV BRITISH COLUMBIA (CA) | 2008-12-31 | — | — | EP | disclosed |
| EP-1997823-A1 | Boronic ester and acid compounds, synthesis and uses | Millennium Pharmaceuticals, Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| US-7439258-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD (CA) | 2008-10-21 | — | — | US | disclosed |
| US-7439258-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD (CA) | 2008-10-21 | — | — | US | disclosed |
| US-7439258-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD (CA) | 2008-10-21 | — | — | US | disclosed |
| US-20080255154-A1 | Cycloalkylcarbonyl-3H-spiro[2-benzofuran-1,3'-pyrrolidin]-3-ones: N-methyl-5-[4-(1-{[3-oxo-1'H,3H-spiro[2-benzofuran-1,3'-pyrrolidin]-1'-yl]carbonyl}cyclopropyl)phenyl]pyridine-2-carboxamide; 11- beta hydroxyl steroid dehydrogenase type 1 inhibitors; mineralcorticoid receptor antagonists; diabetes | INCYTE CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
| EP-1627880-B1 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARM INC (US) | 2008-10-15 | — | — | EP | disclosed |
| CN-101287738-A | Imidazo benzodiazepine derivatives | HOFFMANN LA ROCHE (CH) | 2008-10-15 | — | — | CN | disclosed |
| CN-100422208-C | Hemiasterlin analogs | UNIV BRITISH COLUMBIA (CA) | 2008-10-01 | — | — | CN | disclosed |
| US-20080221181-A1 | COMPOUNDS FOR TREATING TUMORS | WYETH HOLDINGS CORPORATION (US) | 2008-09-11 | — | — | US | disclosed |
| US-7410951-B2 | Biologically active peptides and compositions, their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-08-12 | — | — | US | disclosed |
| US-20080188565-A1 | Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA, LLC | 2008-08-07 | — | — | US | disclosed |
| WO-2008094592-A1 | HYDROXAMIC ACID DERIVATIVES OF ANILINE USEFUL AS THERAPEUTIC AGENTS FOR TREATING ANTHRAX POISONING | PANTHERA BIOPHARNA, LLC (US) | 2008-08-07 | — | — | WO | disclosed |
| EP-1660447-B1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20080167361-A1 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC | 2008-07-10 | — | — | US | disclosed |
| US-20080167361-A1 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC | 2008-07-10 | — | — | US | disclosed |
| US-20080167361-A1 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC | 2008-07-10 | — | — | US | disclosed |
| US-7390910-B2 | Compounds for treating tumors | WYETH (US) | 2008-06-24 | — | — | US | disclosed |
| US-7388023-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2008-06-17 | — | — | US | disclosed |
| US-20080132678-A1 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| WO-2008055847-A1 | ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008055847-A1 | ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-15 | — | — | WO | disclosed |
| US-20080108820-A1 | Hemiasterlin Derivatives and Uses Thereof | EISAI CO., LTD. (JP) | 2008-05-08 | — | — | US | disclosed |
| US-20080108820-A1 | Hemiasterlin Derivatives and Uses Thereof | EISAI CO., LTD. (JP) | 2008-05-08 | — | — | US | disclosed |
| EP-1590326-A4 | SUBSTITUTED ALKYL AMIDO PIPERIDINES | LUNDBECK & CO AS H (DK) | 2008-04-30 | — | — | EP | disclosed |
| US-20080051434-A1 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2008-02-28 | — | — | US | disclosed |
| US-20080051434-A1 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2008-02-28 | — | — | US | disclosed |
| US-20080051429-A1 | USE OF 4-AMINO-PIPERIDINES FOR TREATING SLEEP DISORDERS | ACADIA PHARMACEUTICALS INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080021024-A1 | Metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-01-24 | — | — | US | disclosed |
| WO-2008002671-A2 | METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20070282100-A1 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-7304081-B2 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| CN-101076516-A | Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease | SCHERING CORP (US) | 2007-11-21 | — | — | CN | disclosed |
| EP-1847540-A1 | Nouveaux dérivés d'épothilone, leur procédé de production et leur utilisation pharmaceutique | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-10-24 | — | — | EP | disclosed |
| US-20070225372-A1 | Amides as Bace Inhibitors | ELI LILLY AND COMPANY | 2007-09-27 | — | — | US | disclosed |
| US-20070225372-A1 | Amides as Bace Inhibitors | ELI LILLY AND COMPANY | 2007-09-27 | — | — | US | disclosed |
| US-20070213331-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BASE INHIBITORS | ELI LILLY AND COMPANY | 2007-09-13 | — | — | US | disclosed |
| US-20070213356-A1 | Nitrogen-Containing Heterocyclyl Substituted Imidazoquinolines and Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-09-13 | — | — | US | disclosed |
| US-20070203207-A1 | Heteroaromatic glucokinase activators | BIZZARRO FRED T | 2007-08-30 | — | — | US | disclosed |
| US-7259166-B2 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2007-08-21 | — | — | US | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-7253186-B2 | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARMACEUTICALS, INC. | 2007-08-07 | — | — | US | disclosed |
| US-20070179142-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-08-02 | — | — | US | disclosed |
| CN-1329386-C | Substituted phenylacetamides and their use as glucokinase activators | HOFFMANN LA ROCHE CO LTD (CH) | 2007-08-01 | — | — | CN | disclosed |
| EP-1005465-B1 | NEW EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING SAME AND THEIR PHARMACEUTICAL USE | BAYER SCHERING PHARMA AG (DE) | 2007-07-25 | — | — | EP | disclosed |
| US-20070167522-A1 | Branched carboxylic acid compound and use thereof | ONO PHARMACEUTICAL CO LTD | 2007-07-19 | — | — | US | disclosed |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WANER-LAMBERT COMPANY LLC (US) | 2007-06-07 | — | — | US | disclosed |
| US-7223868-B2 | Such as 2-(3-chloro-phenyl)-3-cyclopentyl-N-thiazol-2-yl-propionamide which increases insulin secretion in treatment of type II diabetes | HOFFMANN-LA ROCHE INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223870-B2 | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction | PFIZER INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20070082890-A1 | Substituted imidazo-[1,5-a][1,2,4]triazolo[1,5-d][1,4] benzodiazepine derivatives | BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT | 2007-04-12 | — | — | US | disclosed |
| US-7199135-B2 | Substituted alkyl amido piperidines | H. LUNDBECK A/S (DK) | 2007-04-03 | — | — | US | disclosed |
| CN-1305475-C | Boronic ester and acid compounds, their synthesis and use | PROSCRIPT INC (US) | 2007-03-21 | — | — | CN | disclosed |
| US-7192972-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-7192972-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-20070049759-A1 | Methods for Preparing N-Arylated Oxazolidinones Via A Copper Catalyzed Cross Coupling | PFIZER INC | 2007-03-01 | — | — | US | disclosed |
| EP-1756063-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20070042968-A1 | Sulfur compounds as inhibitors of Hepatitis C virus NS3 serine protease | SCHERING CORPORATION | 2007-02-22 | — | — | US | disclosed |
| US-20070042968-A1 | Sulfur compounds as inhibitors of Hepatitis C virus NS3 serine protease | SCHERING CORPORATION | 2007-02-22 | — | — | US | disclosed |
| US-20070042968-A1 | Sulfur compounds as inhibitors of Hepatitis C virus NS3 serine protease | SCHERING CORPORATION | 2007-02-22 | — | — | US | disclosed |
| EP-1754700-A2 | Synthesis of oligoketides | Kosan Biosciences, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| US-7179934-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2007-02-20 | — | — | US | disclosed |
| EP-1740575-A2 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1740573-A1 | AMIDES AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1730110-A1 | SULFUR COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2006-12-13 | — | — | EP | disclosed |
| EP-1726590-A1 | CYCLOALKANOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
| EP-1501815-B1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2006-11-22 | — | — | EP | disclosed |
| EP-1301487-B1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM CA LTD (CA) | 2006-11-22 | — | — | EP | disclosed |
| US-20060247282-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | BRAMSON CANDACE | 2006-11-02 | — | — | US | disclosed |
| US-7119080-B2 | For use as inhibitors of proteasome; for reducing the rate of degradation of proteins in an animal | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-20060217418-A1 | Substituted alkyl amido piperidines | H. LUNDBECK A/S (DK) | 2006-09-28 | — | — | US | disclosed |
| US-7112610-B2 | Methods for using amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060205722-A1 | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARMACEUTICALS, INC. | 2006-09-14 | — | — | US | disclosed |
| US-7105671-B2 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-20060199818-A1 | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARMACEUTICALS INC. | 2006-09-07 | — | — | US | disclosed |
| US-20060178429-A1 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | CORBETT WENDY L | 2006-08-10 | — | — | US | disclosed |
| US-20060154972-A1 | Amino acids with affinity for the alpha-2-delta-protein | BARTA NANCY S | 2006-07-13 | — | — | US | disclosed |
| EP-1670452-A2 | METHOD OF USE OF AMINOACIDS HAVING AFFINITY FOR THE A2D PROTEIN | Warner-Lambert Company LLC (US) | 2006-06-21 | — | — | EP | disclosed |
| US-7064147-B2 | Amino acids with affinity for the α-2-delta-protein | WARNER-LAMBERT COMPANY (US) | 2006-06-20 | — | — | US | disclosed |
| EP-1667957-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA-PROTEIN | Warner-Lambert Company LLC (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20060122390-A1 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
| EP-1660447-A1 | CYCLIC AMINE BASE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORPORATION (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1660443-A2 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | SCHERING CORPORATION (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1204652-B1 | NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20060094758-A1 | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARMACEUTICALS, INC. | 2006-05-04 | — | — | US | disclosed |
| EP-1650182-A1 | BRANCHED CARBOXYLIC ACID COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-04-26 | — | — | EP | disclosed |
| US-20060084649-A9 | Substituted alkyl amido piperidines | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2006-04-20 | — | — | US | disclosed |
| EP-1531846-A4 | CONJUGATES OF LIGAND, LINKER AND CYTOTOXIC AGENT AND RELATED COMPOSITIONS AND METHODS OF USE | US GOV HEALTH & HUMAN SERV (US) | 2006-04-19 | — | — | EP | disclosed |
| US-7022825-B2 | Polyketides and antibiotics | KOSAN BIOSCIENCES, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| CN-1245394-C | Substituted phenylacetamides and their use as glucokinase activators | HOFFMANN LA ROCHE (CH) | 2006-03-15 | — | — | CN | disclosed |
| EP-1627880-A1 | Boronic ester and acid compounds, synthesis and uses | Millennium Pharmaceuticals, Inc. (US) | 2006-02-22 | — | — | EP | disclosed |
| EP-1341774-B1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2006-02-01 | — | — | EP | disclosed |
| US-6992103-B2 | Benzamide derivatives, processes for their preparation, and their pharmaceutical use | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-01-31 | — | — | US | disclosed |
| US-RE38947-E1 | Method of enantioselectively catalyzing a reaction | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2006-01-24 | — | — | US | disclosed |
| EP-1614675-A2 | Amino acids with affinity for the alpha-2-delta protein | Warner-Lambert Company LLC (US) | 2006-01-11 | — | — | EP | disclosed |
| EP-1312609-B1 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARM INC (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050282858-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-22 | — | — | US | disclosed |
| US-20050282248-A1 | Chemically modified mutant serine hydrolases show improved catalytic activity and chiral selectivity | JONES JOHN B | 2005-12-22 | — | — | US | disclosed |
| US-20050272667-A1 | Analogs and derivatives of (S,S,R)-(-)-actinonin and uses therefor | SCHEINBERG DAVID | 2005-12-08 | — | — | US | disclosed |
| US-20050272783-A1 | Amino acids with affinity for the alpha2delta-protein | BARTA NANCY SUE | 2005-12-08 | — | — | US | disclosed |
| US-20050261503-A1 | Heteroaromatic glucokinase activators | BIZZARO FRED T | 2005-11-24 | — | — | US | disclosed |
| WO-2005110992-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005108391-A1 | AMIDES AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005108358-A2 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-11-17 | — | — | WO | disclosed |
| CN-1226294-C | Fused heteroaromatic glucokinase activators | HOFFMANN LA ROCHE (CH) | 2005-11-09 | — | — | CN | disclosed |
| EP-1590326-A2 | SUBSTITUTED ALKYL AMIDO PIPERIDINES | H. Lundbeck A/S (DK) | 2005-11-02 | — | — | EP | disclosed |
| EP-1372692-A4 | ASYMMETRIC SYNTHESIS OF (S, S, R)-(-)-ACTINONIN AND ITS ANALOGS AND USES THEREFOR | SLOAN KETTERING INST CANCER (US) | 2005-10-26 | — | — | EP | disclosed |
| US-6951945-B2 | Heteroaromatic glucokinase activators | HOFFMAN-LA ROCHE INC. (US) | 2005-10-04 | — | — | US | disclosed |
| CN-1675201-A | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARM INC (US) | 2005-09-28 | — | — | CN | disclosed |
| WO-2005087731-A1 | SULFUR COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087731-A1 | SULFUR COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-09-22 | — | — | WO | disclosed |
| EP-1562937-A2 | N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS | Acadia Pharmaceuticals Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-1562916-A1 | METHODS FOR PREPARING N-ARYLATED OXAZOLIDINONES VIA A COPPER CATALYZED CROSS COUPLING REACTION | Pfizer Products Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| CN-1653036-A | Amino acids having affinity for the alpha 2 delta protein | WARNER LAMBERT CO (US) | 2005-08-10 | — | — | CN | disclosed |
| US-20050171137-A1 | Biologically active peptides and compositions, their use | THE UNIVERSITY OF BRITISH COLUMBIA | 2005-08-04 | — | — | US | disclosed |
| US-20050171014-A1 | Conjugates of ligand linker and cytotoxic agent and related composition and methods of use | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH (US) | 2005-08-04 | — | — | US | disclosed |
| CN-1649859-A | Substituted phenylacetamides and their use as glucokinase activators | HOFFMANN LA ROCHE (CH) | 2005-08-03 | — | — | CN | disclosed |
| EP-1082127-B1 | SUCCINAMIDE INHIBITORS OF INTERLEUKIN-1BETA CONVERTING ENZYME | WARNER LAMBERT CO (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | disclosed |
| US-20050124669-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | BRAMSON CANDACE (US) | 2005-06-09 | — | — | US | disclosed |
| US-20050119227-A1 | Cyclic amine bace-1 inhibitors having a benzamide substituent | SCHERING CORPORATION | 2005-06-02 | — | — | US | disclosed |
| EP-1531846-A2 | CONJUGATES OF LIGAND, LINKER AND CYTOTOXIC AGENT AND RELATED COMPOSITIONS AND METHODS OF USE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-05-25 | — | — | EP | disclosed |
| US-6897306-B2 | 3-heterocyclylpropanohydroxamic acids | PFIZER PRODUCTS, INC. (US) | 2005-05-24 | — | — | US | disclosed |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-05-12 | — | — | US | disclosed |
| US-20050101651-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | JOHNSON THEODORE O JR (US) | 2005-05-12 | — | — | US | disclosed |
| US-6887887-B2 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2005-05-03 | — | — | US | disclosed |
| US-20050085520-A1 | Benzamide derivatives, processes for their preparation, and their pharmaceutical use | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-04-21 | — | — | US | disclosed |
| WO-2005030184-A2 | THERAPEUTIC BETA AMINOACIDS | WARNER-LAMBERT COMPANY LLC (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030700-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA-PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2005-04-07 | — | — | WO | disclosed |
| US-6872745-B2 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. (US) | 2005-03-29 | — | — | US | disclosed |
| US-6870028-B1 | Biologically active peptides and compositions, their use | UNIVERSITY OF BRITISH COLUMBIA (CA) | 2005-03-22 | — | — | US | disclosed |
| EP-1003775-B1 | HEPATITIS C INHIBITOR PEPTIDES | BOEHRINGER INGELHEIM CA LTD (CA) | 2005-03-16 | — | — | EP | disclosed |
| WO-2005016876-A2 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | SCHERING CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
| WO-2005016958-A2 | COMPOUNDS FOR TREATING TUMORS | WYETH HOLDINGS CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20050043290-A1 | Cyclic amine BACE-1 inhibitors having a heterocyclic substituent | SCHERING CORPORATION AND PHARMACOPEIA DRUG DISCOVERY INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2005014540-A1 | CYCLIC AMINE BASE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORPORATION (US) | 2005-02-17 | — | — | WO | disclosed |
| US-20050037977-A1 | Compounds for treating tumors | WYETH HOLDINGS CORPORATION (US) | 2005-02-17 | — | — | US | disclosed |
| EP-1501815-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-02 | — | — | EP | disclosed |
| US-6849743-B2 | Synthesis of clasto-lactacystin β-lactone and analogs thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| EP-1492761-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | Warner-Lambert Company LLC (US) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003095438-A9 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2004-12-23 | — | — | WO | disclosed |
| EP-1240152-B1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LTD (GB) | 2004-12-08 | — | — | EP | disclosed |
| US-20040224955-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-11-11 | — | — | US | disclosed |
| EP-1282611-B1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2004-10-20 | — | — | EP | disclosed |
| EP-1169312-B1 | GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2004-10-06 | — | — | EP | disclosed |
| EP-1080082-B1 | INTERMEDIATES FOR THE SYNTHESIS OF EPOTHILONES AND METHODS FOR THEIR PREPARATION | NOVARTIS AG (CH) | 2004-10-06 | — | — | EP | disclosed |
| US-20040186103-A1 | Substituted alkyl amido piperidines | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-09-23 | — | — | US | disclosed |
| US-6794404-B2 | BENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-09-21 | — | — | US | disclosed |
| US-6794516-B2 | SYNTHETIC PATHWAY FROM REACTING CHEMICAL INTERMEDIATES 4-CARBOXY OXAZOLINE WITH A FORMYL AMIDE, DECARBOXYLATION, HYDROXYLATION, DECYCLIZATION, LACTAMIZATION, SAPONIFICATION; PROTEASOME INHIBITORS, ANTIINFLAMMATORY, ANTITUMOR AGENTS | MILLENNIUM PHARMACEUTICALS, INC. | 2004-09-21 | — | — | US | disclosed |
| US-20040167332-A1 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-08-26 | — | — | US | disclosed |
| EP-1448520-A1 | BENZAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM PLC (GB) | 2004-08-25 | — | — | EP | disclosed |
| WO-2004064764-A2 | SUBSTITUTED ALKYL AMIDO PIPERIDINES | H. LUNDBECK A/S (DK) | 2004-08-05 | — | — | WO | disclosed |
| US-6767991-B1 | PEPTIDES AND ANALOGS THEREOF; VIRAL PROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH PEPTIDES AND RIBAVIRIN | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-07-27 | — | — | US | disclosed |
| US-20040122226-A1 | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction | PFIZER INC | 2004-06-24 | — | — | US | disclosed |
| US-6747150-B2 | FOR REDUCING RATE OF DEGRADATION OF PROTEINS IN AN ANIMAL; INHIBITING HIV REPLICATION | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-08 | — | — | US | disclosed |
| US-20040106600-A1 | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | disclosed |
| WO-2004039788-A1 | METHODS FOR PREPARING N-ARYLATED OXAZOLIDINONES VIA A COPPER CATALYZED CROSS COUPLING REACTION | PFIZER PRODUCTS INC. (US) | 2004-05-13 | — | — | WO | disclosed |
| EP-0948523-B1 | PEPTIDOMIMETIC INHIBITORS OF THE HUMAN CYTOMEGALOVIRUS PROTEASE | BOEHRINGER INGELHEIM CA LTD (CA) | 2004-03-17 | — | — | EP | disclosed |
| CN-1476438-A | Fused heteroaromatic glucokinase activators | - | 2004-02-18 | — | — | CN | disclosed |
| US-20040019083-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-01-29 | — | — | US | disclosed |
| US-20040014968-A1 | Heteroaromatic glucokinase activators | BIZZARRO FRED THOMAS (US) | 2004-01-22 | — | — | US | disclosed |
| EP-1372692-A2 | ASYMMETRIC SYNTHESIS OF (S, S, R)-(-)-ACTINONIN AND ITS ANALOGS AND USES THEREFOR | Sloan Kettering Institute For Cancer Research (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2004000808-A2 | N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2003-12-31 | — | — | WO | disclosed |
| US-20030232816-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-12-18 | — | — | US | disclosed |
| EP-0839154-B1 | BIOLOGICALLY ACTIVE PEPTIDES AND COMPOSITIONS, THEIR USE | UNIV BRITISH COLUMBIA (CA) | 2003-12-17 | — | — | EP | disclosed |
| US-6660741-B2 | Coupling an O-protected methoxypyrrolidine or derivatives with N-protected amino acid 2,5-dioxo-pyrrolidinyl ester to form intermediate, deportecting with trifluoroacetic acid to form pyrrolidine-1-carbonyl-2-methylamine or derivatives | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-12-09 | — | — | US | disclosed |
| US-20030225283-A1 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | CORBETT WENDY LEA (US) | 2003-12-04 | — | — | US | disclosed |
| US-20030225042-A1 | Antipicornaviral compounds and compositions, their uses, and materials for their synthesis | JOHNSON THEODORE O (US) | 2003-12-04 | — | — | US | disclosed |
| WO-2003095438-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-20 | — | — | WO | disclosed |
| US-6649642-B2 | Useful in the treatment of autoimmune and other cathepsin related diseases. | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030199561-A1 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030195251-A1 | Amino acids with affinity for the alpha-2-delta-protein | BARTA NANCY SUE (US) | 2003-10-16 | — | — | US | disclosed |
| US-20030191322-A1 | Synthesis of clasto-lactacystin beta-lactone and analogs thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-10-09 | — | — | US | disclosed |
| WO-2003082807-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-09 | — | — | WO | disclosed |
| EP-1341774-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-10 | — | — | EP | disclosed |
| US-6617317-B1 | Reducing the rate of degradation of proteins in an animal | MILLENNIUM PHARMACEUTICALS, INC. | 2003-09-09 | — | — | US | disclosed |
| WO-2003072754-A2 | CONJUGATES OF LIGAND, LINKER AND CYTOTOXIC AGENT AND RELATED COMPOSITIONS AND METHODS OF USE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2003-09-04 | — | — | WO | disclosed |
| US-6610846-B1 | Increase insulin secretion; type II diabetes; 2,3-Di-substituted N-heteroaromatic propionamides with 3- a phenyl group and 2- a methyl cycloalkyl ring; 3-cyclopentyl-2-(3,4-dichlorophenyl)-N-pyridazin-3-yl-propionamide | HOFFMAN-LA ROCHE INC. | 2003-08-26 | — | — | US | disclosed |
| US-6610730-B2 | Viricides; protease inbhibitor | AGOURON PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | disclosed |
| US-6610730-B2 | Viricides; protease inbhibitor | AGOURON PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | disclosed |
| CN-1427829-A | Substituted phenylacetamides and their use as glucokinase activators | HOFFMANN LA ROCHE (CH) | 2003-07-02 | — | — | CN | disclosed |
| US-20030119807-A1 | 3-Heterocyclylpropanohydroxamic acids | BAILEY SIMON (US) | 2003-06-26 | — | — | US | disclosed |
| WO-2003045913-A1 | BENZAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-06-05 | — | — | WO | disclosed |
| EP-0788360-B1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARM INC (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20030096374-A1 | Preparation of ketide ester; obtain benzoxazolone derivative, incubate with polyketide synthase, recover ketide oligomer | ASHLEY GARY (US) | 2003-05-22 | — | — | US | disclosed |
| EP-1312609-A1 | Boronic ester and acid compounds, synthesis and uses | Millennium Pharmaceuticals, Inc. (US) | 2003-05-21 | — | — | EP | disclosed |
| US-6566553-B2 | Synthetic pathway relies upon stereospecific synthesis of oxazoline intermediate and stereoselective addition of formyl amide to oxazoline | MILLENNIUM PHARMACEUTICALS, INC. | 2003-05-20 | — | — | US | disclosed |
| US-20030092140-A1 | Novel polyketides and antibiotics | ASHLEY GARY (US) | 2003-05-15 | — | — | US | disclosed |
| US-20030087939-A1 | NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-05-08 | — | — | US | disclosed |
| EP-1301487-A2 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-04-16 | — | — | EP | disclosed |
| US-6548668-B2 | Stabilizer for proteins | MILLENNIUM PHARMACEUTICALS, INC. | 2003-04-15 | — | — | US | disclosed |
| US-6545155-B2 | Useful for increasing insulin secretion in the treatment of type II diabetes | HOFFMANN-LA ROCHE INC. | 2003-04-08 | — | — | US | disclosed |
| US-6528543-B1 | Glucokinase activating for treating type II diabetes; acylurea compound, phenylacetyl-substituted; 1-(2-(3-chloro-phenyl)-3cyclopentyl-propionyl)-3-methyl-urea | HOFFMAN-LA ROCHE INC. | 2003-03-04 | — | — | US | disclosed |
| EP-1282611-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-12 | — | — | EP | disclosed |
| EP-1274682-A2 | ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2003-01-15 | — | — | EP | disclosed |
| US-20020198156-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2002-12-26 | — | — | US | disclosed |
| US-6492562-B1 | INVENTION ALSO RELATES TO NOVEL INTERMEDIATES AND THE RESULTING MODIFIED POLYKETIDES AND ANTIBIOTICS. | KOSAN BIOSCIENCES, INC. | 2002-12-10 | — | — | US | disclosed |
| US-20020173488-A1 | Boronic Ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-11-21 | — | — | US | disclosed |
| US-6479508-B1 | INHIBITOR OF RNA DEPENDENT RNA POLYMERASE ACTIVITY OF THE ENZYME NS5B ENCODED BY HEPATITIS C VIRUS FOR TREATMENT AND PREVENTION OF HEPATITIS C INFECTIONS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-11-12 | — | — | US | disclosed |
| US-6465433-B1 | SUCH AS N-(2-PYRIDINE)CARBONYL-L-PHENYLALANINE-L-LEUCINE BORONIC ACID; PROTEASOME INHIBITORS; REDUCING RATE OF MUSCLE PROTEIN DEGRADATION | MILLENNIUM PHARMACEUTICALS, INC. | 2002-10-15 | — | — | US | disclosed |
| EP-1082127-A4 | SUCCINAMIDE INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | WARNER LAMBERT CO (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2002074050-A2 | ASYMMETRIC SYNTHESIS OF (S, S, R)-(-)-ACTINONIN AND ITS ANALOGS AND USES THEREFOR | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2002-09-26 | — | — | WO | disclosed |
| EP-1240152-A1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | Pfizer Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| US-6448399-B1 | 3-CYCLOALKYL- OR PROPYL-2-(3,4-DIHALOPHENYL)-N-QUINOLINYL-, QUINAZOLINYL-, OR QUINOXOLINYL-PROPIONAMIDE. | HOFFMANN-LA ROCHE INC. | 2002-09-10 | — | — | US | disclosed |
| US-6448281-B1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION; TREATMENT OF HEPATITIS C | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-09-10 | — | — | US | disclosed |
| US-6448278-B2 | ANTISCARRING AGENT | PFIZER INC. | 2002-09-10 | — | — | US | disclosed |
| US-6441184-B1 | SUCH AS N-BENZOOXAZOL-2-YL-3-CYCLOPENTYL-2-(4-METHANESULFONYL -PHENYL)-PROPIONAMIDE FOR INCREASING INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES | HOFFMANN-LA ROCHE INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020111372-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | CORBETT WENDY L (US) | 2002-08-15 | — | — | US | disclosed |
| US-6433188-B1 | ANTIDIABETIC AGENTS | CORBETT WENDY LEA (US) | 2002-08-13 | — | — | US | disclosed |
| US-20020107396-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | CORBETT WENDY LEA (US) | 2002-08-08 | — | — | US | disclosed |
| US-20020103199-A1 | Fused heteroaromatic glucokinase activators | CORBETT WENDY LEA (US) | 2002-08-01 | — | — | US | disclosed |
| US-20020103241-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | CORBETT WENDY L (US) | 2002-08-01 | — | — | US | disclosed |
| WO-2002046173-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-13 | — | — | WO | disclosed |
| US-20020065418-A1 | Inhibitors of hepatitis C virus replication; treatment of hepatitis C | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-05-30 | — | — | US | disclosed |
| EP-1204652-A1 | NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-05-15 | — | — | EP | disclosed |
| US-6384220-B2 | ANTIDIABETIC AGENTS INCREASING THE EXPRESSION OF GLUCOKINASE (GK) TO IMPROVE GLUCOSE TOLERANCE; INCREASE IN GLUCOSE EXPOSURE COUPLED THROUGH GK IN BETA-CELLS TO INCREASE INSULIN SECRETION AND IN HEPATOCYTES TO INCREASE GLYCOGEN DEPOSITION | HOFFMANN-LA ROCHE INC. | 2002-05-07 | — | — | US | disclosed |
| US-6350878-B1 | BASIFICATION AND IODINATION OF ALDEHYDE | NOVARTIS AG (CH) | 2002-02-26 | — | — | US | disclosed |
| US-20020016355-A1 | Synthesis of clasto-lactacystin beta-lactone and analogs thereof | SOUCY FRANCOIS (US) | 2002-02-07 | — | — | US | disclosed |
| EP-0906900-B1 | A process for preparing optically active 2-hydroxy-methyl-3-phenylpropionic acid | AJINOMOTO KK (JP) | 2002-01-23 | — | — | EP | disclosed |
| US-20020006943-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2002-01-17 | — | — | US | disclosed |
| WO-2002004425-A2 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-01-17 | — | — | WO | disclosed |
| EP-1169312-A2 | GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-09 | — | — | EP | disclosed |
| US-20020002190-A1 | Para-aryl or heterocyclic substituted phenyl glucokinase activators | HOFFMANN-LA ROCHE INC. | 2002-01-03 | — | — | US | disclosed |
| EP-0837845-B1 | HERPES RIBONUCLEOTIDE REDUCTASE INHIBITORS | BOEHRINGER INGELHEIM CA LTD (CA) | 2001-11-28 | — | — | EP | disclosed |
| US-6320050-B1 | 2-SUBSTITUTED PHENYL-3-CYCLOALKYL SUBSTITUTED N-HETEROAROMATIC PROPIONAMIDES; USED TO INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES. | HOFFMANN-LA ROCHE INC. | 2001-11-20 | — | — | US | disclosed |
| US-20010041700-A1 | Novel succinate derivative compounds useful as cysteine protease inhibitors | BEKKALI YOUNES (US) | 2001-11-15 | — | — | US | disclosed |
| WO-2001085706-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-15 | — | — | WO | disclosed |
| US-20010039344-A1 | Heteroaromatic glucokinase activators | HOFFMANN-LA ROCHE INC. | 2001-11-08 | — | — | US | disclosed |
| US-6313117-B1 | TREATING AUTOIMMUNE DISORDERS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-11-06 | — | — | US | disclosed |
| WO-2001079167-A2 | ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
| US-6297217-B1 | TREATMENT OF CANCER WITH PROTEASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2001-10-02 | — | — | US | disclosed |
| US-6294560-B1 | DEPROTONATING AN OXAZOLINE WITH STRONG BASE TO FORM AN ENOLATE | MILLENNIUM PHARMACEUTICALS, INC.. | 2001-09-25 | — | — | US | disclosed |
| US-6291640-B1 | OLIGOPEPTIDES; SOLID PHASE SYNTHESIS | BOEHRINGER INGELHEIM LTD. (CA) | 2001-09-18 | — | — | US | disclosed |
| US-20010021718-A1 | Procollagen C-proteinase inhibitors | PFIZER INC. | 2001-09-13 | — | — | US | disclosed |
| EP-1129180-A2 | CHEMICALLY MODIFIED MUTANT SERINE HYDROLASES | GENENCOR INTERNATIONAL, INC. (US) | 2001-09-05 | — | — | EP | disclosed |
| CN-1308542-A | Succinamide inhibitors of interleukin-1 beta converting enzyme | WARNET LAMBERT CO (US) | 2001-08-15 | — | — | CN | disclosed |
| WO-2001047901-A1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LIMITED (GB) | 2001-07-05 | — | — | WO | disclosed |
| EP-1021407-A4 | SYNTHESIS OF CLASTO-LACTACYSTIN BETA-LACTONE AND ANALOGS THEREOF | MILLENNIUM PHARM INC (US) | 2001-07-04 | — | — | EP | disclosed |
| US-6207686-B1 | FOR THERAPY OF HYPERTENSION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-27 | — | — | US | disclosed |
| EP-1082127-A1 | SUCCINAMIDE INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | WARNER-LAMBERT COMPANY (US) | 2001-03-14 | — | — | EP | disclosed |
| EP-1080082-A1 | INTERMEDIATES FOR THE SYNTHESIS OF EPOTHILONES AND METHODS FOR THEIR PREPARATION | Novartis AG (CH) | 2001-03-07 | — | — | EP | disclosed |
| WO-2001009110-A1 | NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
| CN-1282336-A | Hemiasterlin analogs | UNIV BRITISH COLUMBIA (CA) | 2001-01-31 | — | — | CN | disclosed |
| US-6156905-A | Deoxy epothilones and intermediates utilized in the process for preparing epothilones | NOVARTIS AG (CH) | 2000-12-05 | — | — | US | disclosed |
| EP-0618226-B1 | Inhibitors of herpes viral ribonculeotide reductase | BOEHRINGER INGELHEIM CA LTD (CA) | 2000-11-29 | — | — | EP | disclosed |
| CN-1271342-A | Synthesis of clasto-lactacystin-beta-lactone and analogs thereof | SOUCY F (US) | 2000-10-25 | — | — | CN | disclosed |
| US-6133308-A | STEREOSPECIFIC SYNTHESIS OF AN OXAZOLINE INTERMEDIATE AND A UNIQUE STEREOSELECTIVE ADDITION OF A FORMYL AMIDE TO THE OXAZOLINE; USE AS PROTEOSOME INHIBITORS; TREATING INFLAMMATION, ISCHEMIC OR REPERFUSION INJURY IN A MAMMAL | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| WO-2000058293-A2 | GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-05 | — | — | WO | disclosed |
| EP-1040119-A2 | HEMIASTERLIN ANALOGS | UNIVERSITY OF BRITISH COLUMBIA (CA) | 2000-10-04 | — | — | EP | disclosed |
| WO-2000049020-A2 | NOVEL EPOTHILON DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR PHARMACEUTICAL APPLICATION | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-08-24 | — | — | WO | disclosed |
| EP-1021407-A1 | SYNTHESIS OF CLASTO-LACTACYSTIN BETA-LACTONE AND ANALOGS THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2000-07-26 | — | — | EP | disclosed |
| US-6093846-A | BY REACTING WITH SPECIFIED OPTICALLY ACTIVE AMINES SUCH AS CIS-1-AMINO-2-INDANOL IN A SOLVENT, PRODUCING TWO DIASTEREOISOMERIC SALTS OF DIFFERING SOLUBILITY, FRACTIONAL CRYSTALLIZATION AND DECOMPOSING THE SALT WITH ALKALI OR ACID | AJINOMOTO CO., INC. (JP) | 2000-07-25 | — | — | US | disclosed |
| US-6083903-A | REDUCE RATE OF DEGRADATION OF PROTEINS IN ANIMAL | LEUKOSITE, INC. (US) | 2000-07-04 | — | — | US | disclosed |
| EP-1003775-A2 | HEPATITIS C INHIBITOR PEPTIDES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2000-05-31 | — | — | EP | disclosed |
| US-6066730-A | Boronic ester and acid compounds, synthesis and uses | PROSCRIPT, INC. | 2000-05-23 | — | — | US | disclosed |
| WO-2000028007-A2 | CHEMICALLY MODIFIED MUTANT SERINE HYDROLASES | GENENCOR INTERNATIONAL, INC. (US) | 2000-05-18 | — | — | WO | disclosed |
| EP-0621270-B1 | Piperazine derivatives as collagenase inhibitors | SANKYO CO (JP) | 2000-04-12 | — | — | EP | disclosed |
| US-6043372-A | USEFUL CHEMICAL INTERMEDIATES FOR ANTICARCINOGENIC EPITHILONES | NOVARTIS AG (CH) | 2000-03-28 | — | — | US | disclosed |
| US-6028217-A | CHEMICAL INTERMEDIATE FOR RENIN INHIBITOR OR ENKEPHALINASE ENZYME INHIBITOR | AJINOMOTO CO., INC. (JP) | 2000-02-22 | — | — | US | disclosed |
| EP-0776884-B1 | SUBSTITUTED AMIDE DERIVATIVE | BANYU PHARMA CO LTD (JP) | 2000-01-05 | — | — | EP | disclosed |
| EP-0800512-B1 | ANTIHERPES PEPTIDOMIMETIC COMPOUNDS | BOEHRINGER INGELHEIM CA LTD (CA) | 2000-01-05 | — | — | EP | disclosed |
| WO-1999059985-A1 | INTERMEDIATES FOR THE SYNTHESIS OF EPOTHILONES AND METHODS FOR THEIR PREPARATION | NOVARTIS AG (CH) | 1999-11-25 | — | — | WO | disclosed |
| WO-1999056765-A1 | SUCCINAMIDE INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | WARNER-LAMBERT COMPANY (US) | 1999-11-11 | — | — | WO | disclosed |
| US-5969145-A | Process for the production of epothilones and intermediate products within the process | NOVARTIS AG (CH) | 1999-10-19 | — | — | US | disclosed |
| EP-0932598-A1 | ASPARTATE ESTER INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | WARNER-LAMBERT COMPANY (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0696282-B1 | PROCESS FOR PREPARING INTERMEDIATES FOR THE SYNTHESIS OF ANTIFUNGAL AGENTS | SCHERING CORP (US) | 1999-07-14 | — | — | EP | disclosed |
| WO-1999032509-A2 | HEMIASTERLIN ANALOGS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 1999-07-01 | — | — | WO | disclosed |
| EP-0923583-A1 | METHOD FOR PRODUCING EPOTHILONES, AND INTERMEDIATE PRODUCTS OBTAINED DURING THE PRODUCTION PROCESS | Novartis AG (CH) | 1999-06-23 | — | — | EP | disclosed |
| EP-0906900-A1 | A process for preparing optically active 2-hydroxy-methyl-3-phenylpropionic acid | Ajinomoto Co., Inc. (JP) | 1999-04-07 | — | — | EP | disclosed |
| WO-1999009006-A1 | SYNTHESIS OF CLASTO-LACTACYSTIN β-LACTONE AND ANALOGS THEREOF | SOUCY FRANCOIS (US) | 1999-02-25 | — | — | WO | disclosed |
| WO-1999007733-A2 | HEPATITIS C INHIBITOR PEPTIDES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1999-02-18 | — | — | WO | disclosed |
| US-5856322-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, CARDIOVASCULAR DISORDERS | MERCK FROSST CANADA, INC. (CA) | 1999-01-05 | — | — | US | disclosed |
| CN-1041268-C | Method of controlling insects and acarids | FMC CORP (US) | 1998-12-23 | — | — | CN | disclosed |
| US-5846941-A | Isosteric antiherpes peptide derivatives II | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1998-12-08 | — | — | US | disclosed |
| EP-0560267-B1 | Isosteric antiherpes peptide derivatives | BOEHRINGER INGELHEIM CA LTD (CA) | 1998-08-19 | — | — | EP | disclosed |
| US-5780454-A | Boronic ester and acid compounds | PROSCRIPT, INC. (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0839154-A1 | BIOLOGICALLY ACTIVE PEPTIDES AND COMPOSITIONS, THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 1998-05-06 | — | — | EP | disclosed |
| EP-0837845-A1 | HERPES RIBONUCLEOTIDE REDUCTASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1998-04-29 | — | — | EP | disclosed |
| WO-1998016502-A1 | ASPARTATE ESTER INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | WARNER-LAMBERT COMPANY (US) | 1998-04-23 | — | — | WO | disclosed |
| EP-0480717-B1 | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA INC (CA) | 1998-04-15 | — | — | EP | disclosed |
| WO-1998008849-A1 | METHOD FOR PRODUCING EPOTHILONES, AND INTERMEDIATE PRODUCTS OBTAINED DURING THE PRODUCTION PROCESS | NOVARTIS AKTIENGESELLSCHAFT (CH) | 1998-03-05 | — | — | WO | disclosed |
| CN-1168633-A | Boronic ester and acid compounds, their synthesis and use | PROSCRIPT INC (US) | 1997-12-24 | — | — | CN | disclosed |
| US-5693619-A | ENZYME INHIBITORS; ADMINISTERED TO TREAT CONGESTIVE HEART FAILURE AND HYPERTENSION | BOEHRINGER INGELHEIM (CANADA), LTD. (CA) | 1997-12-02 | — | — | US | disclosed |
| EP-0594608-B1 | CHIRAL CATALYSTS FOR ENANTIOSELECTIVE SYNTHESIS | RES CORP TECHNOLOGIES INC (US) | 1997-10-15 | — | — | EP | disclosed |
| US-5672586-A | Herpes ribonucleotide reductase inhibitors | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH, INC. (CA) | 1997-09-30 | — | — | US | disclosed |
| US-5668164-A | Process for synthesis of chiral cis-and trans-3-amino-4 substituted pyrrolidine compounds | ABBOTT LABORATORIES (US) | 1997-09-16 | — | — | US | disclosed |
| EP-0792265-A1 | ENDOTHELIN ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-09-03 | — | — | EP | disclosed |
| EP-0589446-B1 | N-(Hydroxyethyl)butanediamide derivatives as renin inhibitors | BOEHRINGER INGELHEIM CA LTD (CA) | 1997-09-03 | — | — | EP | disclosed |
| US-5643958-A | ANTITUMOR | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1997-07-01 | — | — | US | disclosed |
| US-5643908-A | ANGIOGENESIS INHIBITOR, ANTITUMOR | SANKYO COMPANY, LIMITED (JP) | 1997-07-01 | — | — | US | disclosed |
| EP-0482771-B1 | Heterocyclic acids | ZENECA LTD (GB) | 1997-06-18 | — | — | EP | disclosed |
| EP-0776884-A1 | SUBSTITUTED AMIDE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1997-06-04 | — | — | EP | disclosed |
| EP-0767671-A1 | METHOD OF COMBATING ACYCLOVIR-RESISTANT HERPES SIMPLEX VIRAL INFECTIONS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1997-04-16 | — | — | EP | disclosed |
| US-5618949-A | Process for synthesis of chiral cis- and trans-3-amino-4-substituted pyrrolidine compounds | ABBOTT LABORATORIES (US) | 1997-04-08 | — | — | US | disclosed |
| EP-0589445-B1 | Renin Inhibiting N-(2-Amino-2-oxoethyl)Butanediamide Derivatives | BIO MEGA BOEHRINGER INGELHEIM (CA) | 1997-01-15 | — | — | EP | disclosed |
| US-5594006-A | SUCH AS COLLEGENASE, STROMELYSIN; ANTICANCER AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-01-14 | — | — | US | disclosed |
| WO-1997000855-A1 | HERPES RIBONUCLEOTIDE REDUCTASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD./BOEHRINGER INGELHEIM (CANADA) LTÉE. (CA) | 1997-01-09 | — | — | WO | disclosed |
| US-5574015-A | Isosteric antiherpes peptide derivatives | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1996-11-12 | — | — | US | disclosed |
| WO-1996033211-A1 | BIOLOGICALLY ACTIVE PEPTIDES AND COMPOSITIONS, THEIR USE | UNIVERSITY OF BRITISH COLUMBIA (CA) | 1996-10-24 | — | — | WO | disclosed |
| US-5565473-A | USEFUL AS ANTI-ASTHMATIC, ANTI-ALLERGIC, ANTI-INFLAMMATORY AND CYTOPROTECTIVE AGENTS; MONTELUKAST AND ITS SODIUM SALT | MERCK FROSST CANADA, INC. (CA) | 1996-10-15 | — | — | US | disclosed |
| US-5565476-A | RENIN INHIBITORS FOR TREATMENT OF CONGESTIVE HEART FAILURE AND HYPERTENSION | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1996-10-15 | — | — | US | disclosed |
| US-5554634-A | HYPOTENSIVE | BIO-MEGA BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1996-09-10 | — | — | US | disclosed |
| US-5541163-A | HYPOTENSIVE AGENTS | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1996-07-30 | — | — | US | disclosed |
| US-5523315-A | N-(hydroxyethyl)butanediamide derivatives | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1996-06-04 | — | — | US | disclosed |
| WO-1996015109-A1 | ENDOTHELIN ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-05-23 | — | — | WO | disclosed |
| EP-0365328-B1 | Pyridine derivatives | ZENECA LTD (GB) | 1996-04-03 | — | — | EP | disclosed |
| CN-1118601-A | Inhibitors of herpes viral ribonucleotide reductase | BIO MEGA BOEHRINGER INGELHEIM (CA) | 1996-03-13 | — | — | CN | disclosed |
| EP-0696282-A1 | PROCESS FOR PREPARING INTERMEDIATES FOR THE SYNTHESIS OF ANTIFUNGAL AGENTS | SCHERING CORPORATION (US) | 1996-02-14 | — | — | EP | disclosed |
| WO-1996002521-A1 | RESOLUTION PROCESS USING OXAZOLIDINONES | ALBEMARLE CORPORATION (US) | 1996-02-01 | — | — | WO | disclosed |
| US-5476841-A | Inhibitors of herpes viral ribonucleotide reductase | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1995-12-19 | — | — | US | disclosed |
| US-5410064-A | Thromboxane A2 antagonists and inhibitors of thromboxane A2 synthase | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-04-25 | — | — | US | disclosed |
| US-5403937-A | Process for preparing intermediates for the synthesis of antifungal agents | SCHERING CORPORATION (US) | 1995-04-04 | — | — | US | disclosed |
| US-5401849-A | FOR ANTAGONIZING THE ACTIONS OF, AND INHIBITING THE SYNTHESIS OF, THROMBOXANE A2 | ZENECA LIMITED (GB) | 1995-03-28 | — | — | US | disclosed |
| US-5391819-A | Process of making chiral 2-aryl-1,4-butanediamine derivatives as useful neurokinin-A antagonists | MERCK & CO., INC. (US) | 1995-02-21 | — | — | US | disclosed |
| US-5378689-A | Hypotensive agents; administrable by mouth | SANKYO COMPANY, LIMITED (JP) | 1995-01-03 | — | — | US | disclosed |
| US-5378690-A | Treatment of angiotensin induced hypertension | SANKYO COMPANY, LIMITED (JP) | 1995-01-03 | — | — | US | disclosed |
| EP-0489548-B1 | A process for the preparation of 2(R)-methyl-4,4,4-trifluorobutylamine, intermediates, and a process for the preparation of a derivative thereof | ZENECA LTD (GB) | 1994-12-14 | — | — | EP | disclosed |
| US-5364844-A | Hypotensive agents | SANKYO COMPANY, LIMITED (JP) | 1994-11-15 | — | — | US | disclosed |
| WO-1994025452-A1 | PROCESS FOR PREPARING INTERMEDIATES FOR THE SYNTHESIS OF ANTIFUNGAL AGENTS | SCHERING CORPORATION (US) | 1994-11-10 | — | — | WO | disclosed |
| WO-1994025046-A1 | METHOD OF COMBATING ACYCLOVIR-RESISTANT HERPES SIMPLEX VIRAL INFECTIONS | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-11-10 | — | — | WO | disclosed |
| EP-0290145-B1 | Aliphatic carboxamides | ICI AMERICA INC (US) | 1994-10-26 | — | — | EP | disclosed |
| EP-0621270-A1 | COLLAGENASE INHIBITOR | SANKYO COMPANY LIMITED (JP) | 1994-10-26 | — | — | EP | disclosed |
| EP-0618226-A1 | Inhibitors of herpes viral ribonculeotide reductase | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-10-05 | — | — | EP | disclosed |
| WO-1994021612-A1 | CARBOSTYRIL DERIVATIVES AS MATRIX METALLOPROTEINASES INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-09-29 | — | — | WO | disclosed |
| EP-0329360-B1 | Pyridine derivatives | ICI PLC (GB) | 1994-08-03 | — | — | EP | disclosed |
| CN-1090278-A | Blood vessel tension peptide protoenzyme inhibitor-N-(2-amino-2-oxygen ethyl) succinic diamide derivative | BIO MEGA BOEHRINGER INGELHEIM (CA) | 1994-08-03 | — | — | CN | disclosed |
| EP-0197432-B1 | Enantioselective process for producing 1-beta-methylcarbapenem antibiotic intermediates | MERCK & CO INC (US) | 1994-06-15 | — | — | EP | disclosed |
| EP-0594608-A1 | CHIRAL CATALYSTS FOR ENANTIOSELECTIVE SYNTHESIS. | RES CORP TECHNOLOGIES INC (US) | 1994-05-04 | — | — | EP | disclosed |
| WO-1994007846-A1 | RENIN INHIBITING N-(2-AMINO-2-OXOETHYL)BUTANEDIAMIDE DERIVATIVES | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-04-14 | — | — | WO | disclosed |
| WO-1994007845-A1 | N-(HYDROXYETHYL)BUTANEDIAMIDE DERIVATIVES AS RENIN INHIBITORS | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-04-14 | — | — | WO | disclosed |
| EP-0589445-A1 | Renin Inhibiting N-(2-Amino-2-oxoethyl)Butanediamide Derivatives | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-03-30 | — | — | EP | disclosed |
| EP-0589446-A1 | N-(Hydroxyethyl)butanediamide derivatives as renin inhibitors | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-03-30 | — | — | EP | disclosed |
| US-5298526-A | Optically pure stereogenically labile 4-substituted-2-hydroxytetronic acids and pharmaceutical use | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1994-03-29 | — | — | US | disclosed |
| US-5296595-A | Metal complexes with bridging ligands | RESEARCH CORPORATION TECHNOLOGIES (US) | 1994-03-22 | — | — | US | disclosed |
| EP-0385664-B1 | Antiinflammatory benzoxazolones | PFIZER (US) | 1994-01-12 | — | — | EP | disclosed |
| US-5274118-A | Process for preparing (2R)-methyl-4,4,4-trifluorobutylamine | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-12-28 | — | — | US | disclosed |
| US-5270324-A | Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1993-12-14 | — | — | US | disclosed |
| US-5248780-A | Thromboxane inhibitors | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1993-09-28 | — | — | US | disclosed |
| WO-1993018056-A1 | ISOSTERIC ANTIHERPES PEPTIDE DERIVATIVES | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-16 | — | — | WO | disclosed |
| EP-0560267-A1 | Isosteric antiherpes peptide derivatives | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-15 | — | — | EP | disclosed |
| US-5231179-A | Heterocyclic compounds and their production | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1993-07-27 | — | — | US | disclosed |
| US-5219874-A | Heterocyclic acids | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-06-15 | — | — | US | disclosed |
| US-5202321-A | Antihistamine, antiallergens, antiinflammatory agents | MERCK FROSST CANADA, INC. (CA) | 1993-04-13 | — | — | US | disclosed |
| EP-0594608-A4 | CHIRAL CATALYSTS FOR ENANTIOSELECTIVE SYNTHESIS. | RES CORP TECHNOLOGIES INC (US) | 1993-03-15 | — | — | EP | disclosed |
| US-5179208-A | Analgesics | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 1993-01-12 | — | — | US | disclosed |
| US-5175311-A | Reacting olefin with carbene precursor | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1992-12-29 | — | — | US | disclosed |
| EP-0518426-A1 | Thiopyrano (2,3,4-c,d) indoles as inhibitors of leukotriene biosynthesis | MERCK FROSST CANADA INC. (CA) | 1992-12-16 | — | — | EP | disclosed |
| US-5166213-A | Antiischemic agents, cardiovascular disorders, antiasthmatics or antiinflammatory agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-11-24 | — | — | US | disclosed |
| EP-0357610-B1 | INSECTICIDAL CYCLOPROPYL-SUBSTITUTED DI(ARYL) COMPOUNDS | FMC Corporation (US) | 1992-09-16 | — | — | EP | disclosed |
| US-5145993-A | Process for preparing D-2-(6-methoxy-2-naphthyl)-propionic acid and intermediate thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 1992-09-08 | — | — | US | disclosed |
| EP-0489548-A1 | A process for the preparation of 2(R)-methyl-4,4,4-trifluorobutylamine, intermediates, and a process for the preparation of a derivative thereof | ZENECA LIMITED (GB) | 1992-06-10 | — | — | EP | disclosed |
| EP-0482771-A2 | Heterocyclic acids | ZENECA LIMITED (GB) | 1992-04-29 | — | — | EP | disclosed |
| EP-0480717-A1 | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1992-04-15 | — | — | EP | disclosed |
| US-5104869-A | Renin inhibitors | AMERICAN CYANAMID COMPANY (US) | 1992-04-14 | — | — | US | disclosed |
| US-5104984-A | Enantioselective process for producing 1-beta-methyl carbapenem antibiotic intermediates | MERCK & CO., INC. (US) | 1992-04-14 | — | — | US | disclosed |
| EP-0232786-B1 | HETEROCYCLIC COMPOUNDS AND THEIR PRODUCTION | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1992-04-08 | — | — | EP | disclosed |
| US-5095126-A | Efficient synthesis for optically pure stereogenically labile 4-substituted-2-hydroxytetronic acids | OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1992-03-10 | — | — | US | disclosed |
| US-5086062-A | Inhibitors of lipoxygenase and-or cyclooxygenase enzymes | PFIZER INC. (US) | 1992-02-04 | — | — | US | disclosed |
| WO-1991014672-A1 | CHIRAL CATALYSTS FOR ENANTIOSELECTIVE SYNTHESIS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1991-10-03 | — | — | WO | disclosed |
| US-5053415-A | Antiischemic, antiinflammatory, antiarthritic agents, cardiovascular disorders | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-10-01 | — | — | US | disclosed |
| EP-0427939-A2 | Renin inhibitors | AMERICAN CYANAMID COMPANY (US) | 1991-05-22 | — | — | EP | disclosed |
| EP-0385664-A2 | Antiinflammatory benzoxazolones | PFIZER INC. (US) | 1990-09-05 | — | — | EP | disclosed |
| EP-0365328-A2 | Pyridine derivatives | ZENECA LIMITED (GB) | 1990-04-25 | — | — | EP | disclosed |
| EP-0357610-A1 | INSECTICIDAL CYCLOPROPYL-SUBSTITUTED DI(ARYL) COMPOUNDS. | FMC CORP (US) | 1990-03-14 | — | — | EP | disclosed |
| US-4894386-A | ANTIINFLAMMATORY AGENTS | ICI AMERICAS INC. (US) | 1990-01-16 | — | — | US | disclosed |
| EP-0342541-A2 | Retroviral protease inhibitors | ABBOTT LABORATORIES (US) | 1989-11-23 | — | — | EP | disclosed |
| EP-0329360-A2 | Pyridine derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-08-23 | — | — | EP | disclosed |
| EP-0326364-A2 | Renin inhibitory oligopeptides, their preparation and use | Sankyo Company Limited (JP) | 1989-08-02 | — | — | EP | disclosed |
| US-4808762-A | Insecticidal cyclopropyl-substituted di(aryl) compounds | FMC CORPORATION (US) | 1989-02-28 | — | — | US | disclosed |
| US-4791207-A | THIA- OR OXAZOLIDINONES | MERCK & CO., INC. (US) | 1988-12-13 | — | — | US | disclosed |
| WO-1988008416-A1 | INSECTICIDAL CYCLOPROPYL-SUBSTITUTED DI(ARYL) COMPOUNDS | FMC CORPORATION (US) | 1988-11-03 | — | — | WO | disclosed |
| EP-0274259-A2 | New renin-inhibitory oligopeptides, their preparaton and their use | Sankyo Company Limited (JP) | 1988-07-13 | — | — | EP | disclosed |
| EP-0232786-A1 | Heterocyclic compounds and their production | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1987-08-19 | — | — | EP | disclosed |
| EP-0232786-A1 | Heterocyclic compounds and their production | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1987-08-19 | — | — | EP | disclosed |